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ABSTRACT 
 
Anu Koskela 
 
The brain serotonin transporter binding in young adults; methodological 
considerations and association with bulimia nervosa and acquired obesity 
 
Serotonin (5-HT) is one of the brain neurotransmitters, and it modulates many functions 
important for life, including appetite, body temperature, sexual drive and circadian 
rhythms. It is also involved in controlling the development of the neural system during 
gestation and infancy, and is likely to play a role in adult neurogenesis. Disturbed 5-HT 
function is implicated in several psychiatric disorders, including mood, anxiety and 
eating disorders. Its actions on feeding behavior make it also an interesting target in 
obesity research. The amount of effective 5-HT in the extracellular space is controlled 
by the serotonin transporter (SERT), which terminates 5-HT’s action by removing it 
from the extracellular space. Medications acting on SERTs are widely used in treatment 
of psychiatric disorders, and to some extent also as antiobesity drugs. In vivo 
investigations of the brain SERTs are possible by using the radionuclide imaging 
methods single photon emission tomography (SPET) and positron emission 
tomography (PET).  
 
The aim of this thesis was to investigate methodological aspects of SERT imaging 
with SPET. This was achieved by comparing different methods for defining target 
regions, and by investigating the existence of physiological seasonal variation in SERT 
binding between summer and winter scans. Further aims included investigating the 
association of SERTs and Bulimia Nervosa, and the association between SERTs and 
acquired obesity.   
 
The study population consisted of young adults, most of whom were monozygotic 
(MZ) or dizygotic (DZ) twins recruited from the national FinnTwin16 twin cohort. Two 
radioligands for SERT imaging, [123I]ADAM and [123I]nor-β-CIT, were used. The first 
study validated the use of an automated brain template in the analyses of [123I]ADAM 
images. The second study investigated within-subject variation in SERT binding of 
[123I]ADAM between scans done in summer and winter, and found no systematic 
variation in the regions investigated (midbrain and thalamus). The third and fourth 
studies applied twin study designs. The third study compared SERT binding of 
[123I]ADAM between BN women, their unaffected co-twin sisters (MZ or DZ), and 
unrelated healthy twin women. No significant differences were found between the three 
groups in the midbrain or thalamus areas, and the unaffected co-twins had similar 
SERT binding as the unrelated healthy control women in both investigated areas. In 
post hoc analyses, a subgroup of purging BN women had significantly higher SERT 
binding in the midbrain as compared to all healthy women. In the fourth study, MZ 
twin pairs were divided into twins with higher body mass index (BMI) and co-twins 
with lower BMI; twins with higher BMI were found to have higher SERT binding of 
[123I]nor-β-CIT in the hypothalamus/thalamus than their leaner co-twins.  
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Based on our results, the following conclusions can be made: 1) No systematic 
seasonal variation exists between SERT binding in summer and winter in the midbrain 
and thalamus regions. This further suggests that seasonal variation does not need to be 
considered as significant confounding factor in studies assessing SERT binding in these 
areas. 2) In a population-based sample, BN does not associate with altered SERT status 
as such, but in purging BN women such alterations are possible. 2) The higher SERT 
binding in MZ twins with higher BMIs as compared to their leaner co-twins suggests 
non-genetic effect of body weight and acquired obesity on the brain SERT binding and 
the 5-HT system, which may have implications regarding feeding behavior and satiety. 
These studies add to the existing literature on physiological regulation of SERTs, 
association between 5-HT function and BN, and 5-HT function and obesity. 
 3 
 TABLE OF CONTENTS  
 
ABSTRACT.........................................................................................................................................1 
TABLE OF CONTENTS.....................................................................................................................3 
LIST OF ABBREVIATIONS..............................................................................................................5 
LIST OF ORIGINAL PUBLICATIONS.............................................................................................7 
1. INTRODUCTION ...........................................................................................................................8 
2. REVIEW OF THE LITERATURE................................................................................................10 
2.1 SEROTONIN (5-HT)...............................................................................................................10 
2.1.1. Overview..........................................................................................................................10 
2.1.2. 5-HT synthesis and degradation.......................................................................................10 
2.1.3. 5-HT neurons ...................................................................................................................11 
2.1.4. 5-HT receptors .................................................................................................................12 
2.1.5. The serotonin transporter .................................................................................................14 
2.2. THE SEROTONIN TRANSPORTER (SERT) ......................................................................15 
2.2.1. Overview..........................................................................................................................15 
2.2.2. Genetic variation of gene coding for SERT.....................................................................16 
2.2.3. Regulation of the SERTs..................................................................................................18 
2.2.3.1. Short-term regulation ................................................................................................18 
2.2.3.2. Long-term regulation ................................................................................................20 
2.2.3.3. Factors that may cause long-term regulation of SERTs ...........................................20 
2.2.3.3.1. Chronic drug administration ..............................................................................20 
2.2.3.3.2. Aging..................................................................................................................20 
2.2.3.3.3. Gender and sex steroids .....................................................................................20 
2.2.3.3.4. Seasons and the amount of light ........................................................................21 
2.2.3.3.5. Tobacco, alcohol and drugs of abuse .................................................................22 
2.3. IMAGING OF THE BRAIN 5-HT SYSTEM ........................................................................22 
2.3.1 Emission tomography methods.........................................................................................22 
2.3.1.1 Overview....................................................................................................................22 
2.3.1.2. Principles of SPET....................................................................................................23 
2.3.1.3. Principles of PET ......................................................................................................23 
2.3.1.4. Quantification methods .............................................................................................24 
2.3.1.4.1. Tracer kinetic modelling ....................................................................................24 
2.3.1.4.2. Definition of target regions ................................................................................25 
2.3.2. Radioligands for imaging of the brain 5-HT system........................................................26 
2.3.2.1. 5-HT synthesis and neuronal activity........................................................................26 
2.3.2.2. 5-HT receptors ..........................................................................................................26 
2.3.2.3. Serotonin transporters ...............................................................................................26 
2.4. BULIMIA NERVOSA............................................................................................................28 
2.4.1. Clinical characteristics and epidemiology .......................................................................28 
2.4.2. Etiology............................................................................................................................29 
2.4.3. 5-HT function in Bulimia Nervosa ..................................................................................30 
2.4.4. Treatment .........................................................................................................................31 
2.5. OBESITY................................................................................................................................31 
2.5.1. Overview..........................................................................................................................31 
2.5.2. 5-HT and feeding behavior ..............................................................................................32 
3. STUDY OBJECTIVES..................................................................................................................34 
 4 
4. METHODS ....................................................................................................................................35 
4.1. STUDY DESIGN....................................................................................................................35 
4.2. STUDY SUBJECTS ...............................................................................................................36 
4.2.1. Studies I-III ......................................................................................................................37 
4.2.1.1. Recruitment of study subjects ...................................................................................37 
4.2.1.2. Study subjects in each study I-III..............................................................................37 
4.2.2. Study IV ...........................................................................................................................38 
4.3. ASSESSMENT OF CLINICAL, PSYCHIATRIC AND BEHAVIOURAL 
CHARACTERISTICS ...................................................................................................................39 
4.4. ASSESSMENT OF ZYGOSITY............................................................................................40 
4.5. SERT IMAGING ....................................................................................................................40 
4.5.1. Radioligands.....................................................................................................................40 
4.5.1.1. [123I]ADAM ..............................................................................................................40 
4.5.1.2. [123I]nor-β-CIT ..........................................................................................................40 
4.5.2. SPET procedures..............................................................................................................41 
4.5.2.1. SPET studies using [123I]ADAM ..............................................................................41 
4.5.2.2. SPET studies using [123I]nor-β-CIT..........................................................................42 
4.5. STATISTICAL ANALYSES .................................................................................................43 
5. RESULTS ......................................................................................................................................45 
5.1. COMPARISON OF REPRODUCIBILITY OF MANUAL AND AUTOMATED 
QUANTIFICATION TECHNIQUES FOR SERT BINDING IN STUDIES WITH [123I]ADAM
........................................................................................................................................................45 
5.2. Seasonal variation in SERT binding of [123I]ADAM..............................................................47 
5.3. SERT AVAILABILITY IN SUBJECTS AFFECTED BY OR GENETICALLY 
PREDISPOSED TO BULIMIA NERVOSA.................................................................................48 
5.3.1. Demographic variables and behavioural assessments .....................................................48 
5.3.2. SERT binding in women with BN, their unaffected sisters and non-related healthy twin 
women........................................................................................................................................48 
5.3.3. The effect of past psychiatric comorbidities on individual data ......................................49 
5.3.4. Within-pair comparisons of SERT binding .....................................................................49 
5.4. RELATIONSHIP BETWEEN BODY MASS INDEX AND THE BRAIN SERT BINDING
........................................................................................................................................................51 
5.4.1. BMI and SERT binding in individuals ............................................................................51 
5.4.2. BMI and SERT binding in twin pairs ..............................................................................51 
6. DISCUSSION ................................................................................................................................53 
6.1. METHODOLOGICAL CONSIDERATIONS .......................................................................53 
6.1.1. Definition of volumes of interest .....................................................................................53 
6.1.2. The radioligands...............................................................................................................54 
6.1.3. Relationship between 5-HT levels and SERT binding ....................................................56 
6.1.4. Other methodological considerations...............................................................................57 
6.2. Seasonal variation in the brain SERT binding ........................................................................59 
6.3. SERT BINDING IN SUBJECTS AFFECTED BY OR GENETICALLY PREDISPOSED 
TO BULIMIA NERVOSA ............................................................................................................60 
6.4. Association between SERT binding and BMI ........................................................................63 
7. SUMMARY AND CONCLUSIONS ............................................................................................66 
8. ACKNOWLEDGEMENTS...........................................................................................................67 
9. REFERENCES...............................................................................................................................70 
 
 5 
LIST OF ABBREVIATIONS 
 
5-HIIA  5-hydroxyindolacetic acid 
5-HT  Serotonin, 5-hydroxytryptamine 
5-HTP  5-hydroxytrytophan  
5-HTTLPR 5-HTT gene-linked polymorphic region 
A3ARs  A3 adenosine receptors  
ACh  Acetylcholine 
[123I] ADAM [123I]-2-((2-((dimethylamino)-methyl)phenyl)thio)-5-
iodophenylamine        
AgRP  Agouti Related Protein 
AN  Anorexia Nervosa 
ATD   Acute tryptophan depletion 
BED  Binge Eating Disorder 
BDNF   Brain derived neurotrophic factor 
Bmax   Total concentration of receptors 
BMI  Body Mass Index 
BN  Bulimia Nervosa 
BP   Binding potential (Bmax/ Kd) 
cAMP  cyclic adenosine monophosphate 
[11C]5-HTP 5-Hydroxy-L-[β-11C]tryptophan  
[11C]-αMtrp  [11C]-α-methyl-L-tryptophan  
CBT   Cognitive behavioral therapy 
CNS  Central nervous system 
COMT  Catechol-O-methyl transferase 
CREB  cAMP response element-binding 
CT   Computed tomography 
DA  Dopamine 
DAG  Diacylglycerol 
DAT  Dopamine transporter 
DSM-IV  Diagnostic and Statistical Manual of Mental Disorders, Fourth 
edition 
DV  Distribution volume 
DVR  Distribution volume ratio 
DZ  Dizygotic 
17β-E  17β-estradiol 
E  Epinephrine 
fMRI  Functional magnetic resonance imaging 
GABA  Gamma-aminobutyric acid 
[123I]β-CIT [123I]methyl 3 beta- (4-iodophenyl) tropane-2 beta-carboxylate   
[123I]nor-β-CIT [123I]2beta-carbomethoxy-3beta-(4-iodophenyl)  
IL-1β  interleukin 1 beta 
ICC  Intra-class correlation coefficient 
 6 
IP3  inositol-tris-phosphate 
kcts  kilocounts 
Kd  Equilibrium dissociation constant 
keV  kiloelectronVolt 
MAO  Monoamine oxidase 
MAPK  Mitogen activated protein kinase 
MBq  MegaBecquerel 
MD  Medical doctor 
MDD  Major depressive disorder 
MDMA  3,4-methylenedioxy-N-methylamphetamine (extasy) 
MRI  Magnetic resonance imaging 
mRNA  messenger ribonucleic acid 
α-MSH  α-Melanocyte stimulating hormone 
MZ  Monozygotic 
mSv  milliSievert 
NE  Norepinephrine 
NET  Norepinephrine transporter 
OCD  Obsessive compulsive disorder 
P   Progesterone 
PET  Positron emission tomography 
PK  Proteinkinase (PKA, PKC, PKG)  
PLC  Phospholipase C 
POMC  Pro-opiomelanocortin 
PP  Protein phosphatase (PP1, PP2) 
PTK  Protein tyrosine kinase 
PVE  Partial volume effect 
ROI  Region of interest 
SAD  Seasonal affective disorder 
SBR  Specific binding ratio 
SERT  Serotonin transporter (SLC6A4, 5-HTT) 
SLC6A4  Gene coding for serotonin transporter 
SNP  Single nucleotide polymorphism 
SPE(C)T Single photon emission (computed) tomography 
SPM   Statistical Parametric Mapping 
SRTM  Simplified reference tissue model 
SSAGA  Semi-Structured Assessment for the Genetics of Alcoholism 
SSRI  Selective serotonin reuptake inhibitor 
SUR   Specific uptake ratio (= SBR) 
TNF-α  Tumor necrosis factor-alpha 
TRP  Tryptophan 
VNTR  Variable number tandem repeat 
VOI  Volume of interest 
 7 
LIST OF ORIGINAL PUBLICATIONS 
 
This thesis is based on the following original publications which are referred to in the 
text by the Roman numerals I-IV: 
 
 
I Kauppinen T., Koskela A., Diemling M., Keski-Rahkonen A., Sihvola E, Ahonen A.: 
Comparison of manual and automated quantification methods of [123I]ADAM. 
Nuklearmedizin 2005; 44:205-212. 
 
II Koskela A., Kauppinen T., Keski-Rahkonen A., Sihvola E., Kaprio J., Rissanen A. 
and Ahonen A.: The brain serotonin transporter binding of [123I]ADAM: within-subject 
variation between summer and winter data. Chronobiology Int (in press).  
 
II Koskela A. K., Keski-Rahkonen A., Sihvola E., Kauppinen T., Kaprio J., Rissanen 
A., Ahonen A.: Serotonin transporter binding of [123I]ADAM in bulimic women, their 
sisters and healthy women: A SPET study. BMC Psychiatry 2007;7:19. 
 
IV Koskela A. K., Kaurijoki S., Pietiläinen K.P., Karhunen L., Kuikka J., Kaprio J. and 
Rissanen A.: Serotonin Transporter Binding and Acquired Obesity – an Imaging Study 
of Monozygotic Twin Pairs. Physiol Behav 2008;93:724-32. 
 8 
1. INTRODUCTION 
 
Serotonin (5-HT) is one of the brain monoamine neurotransmitters, and it modulates the 
homeostasis of several systems that are important for life, e.g., body temperature, 
appetite, sexual drive, and circadian rhythms. Its actions are also implicated in 
modulation of emotions, cognition, motor function and pain (1). Furthermore, recent 
studies have shown that it affects the development of the neural system during gestation 
and infancy (2) as well as neurogenesis in adults (3). Disturbances of 5-HT function are 
believed to play a role in the pathophysiology of many psychiatric disorders, e.g. 
anxiety (4), mood disorders (5), eating disorders (6), obsessive compulsive disease 
(OCD) (7) and impulsivity and aggression (8,9). Medications acting on 5-HT system 
are used in treatment of these disorders (10), as well as anti-obesity drugs (11).  
 
5-HT was established as a neurotransmitter in the 1950’s, and its role in the 
development of mental illnesses was first suggested in the 1960’s (12). Since then 
thousands of studies have aimed to investigate its role. The methods for studying the 5-
HT system have evolved during this time. While animal models have allowed direct 
experiments of the brain 5-HT system, their results cannot be directly applied to 
humans due to species differences. Until recently, central 5-HT system in humans could 
only be investigated indirectly, by measuring peripheral responses to agents influencing 
the central 5-HT system; direct investigations were possible only in post mortem brains. 
Since the early 1990’s, in vivo studies of brain neurotransmitter systems have been 
performed using imaging methods applying radioactive isotopes, i.e. single photon 
emission tomography (SPET) and positron emission tomography (PET). Initially, the 
number of suitable radioligands was small, allowing limited studies on few 
neurotransmitter systems. During the last few years, the number of available targets and 
ligands has increased. This development is sure to continue, and we are only beginning 
to understand all the things that need to be considered when investigating these 
complicated systems. 
 
Eating disorders Anorexia Nervosa (AN) and Bulimia Nervosa (BN) are important 
psychiatric disorders affecting predominantly adolescent girls and women (13), while 
the most common eating disorder, Binge Eating Disorder (BED), affects both men and 
women (14). Given 5-HT’s role in the regulation of appetite (11), anxiety (4) and 
impulsive behavior (15), 5-HT could theoretically play a role in the pathophysiology of 
eating disorders. Several studies investigating indirect measures of central 5-HT 
function have supported its role both in AN and BN (6), and in BN, medications acting 
on the 5-HT system are known to alleviate symptoms (16). To date, only few imaging 
studies have investigated the brain 5-HT system in eating disorders, and some 
uncertainty remains regarding 5-HT’s role. Furthermore, if dysfunction of the 5-HT 
system underlies eating disorders, it is of interest to know whether disturbances are 
present before the onset of symptoms, representing an eating disorder specific 
endophenotype, i.e., genetic neurobiological vulnerability for the disorder. 
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Obesity is one of the main health issues of our time, developing as a consequence of 
imbalance between ingested and expended energy. The rapid increase in its prevalence 
suggests a major involvement of environmental factors, of which excessive supply of 
food together with western sedentary lifestyle is considered as most important (17).  
However, the complicated mechanisms behind appetite and feeding behavior, involving 
interplay of peripheral and central control mechanisms (18), are still not fully 
understood. In brain, more than forty signalling molecules affecting feeding behavior 
are known (19), and 5-HT is one of them, having an anorexigenic effect. Given the 
rapid spread of obesity and its role as a major risk factor for several chronic diseases 
and associated mortality, understanding all the causative mechanisms is of paramount 
importance. Despite this, only few neuroimaging studies on obesity and 
neurotransmitters have been published to date, and they have concentrated on the 
dopamine system (20-23).  
 
This thesis focuses on the brain serotonin transporters (SERTs), which are proteins 
responsible for reuptake of 5-HT from the extracellular space and thus control the 
amount of effective 5-HT. The work presented concentrates on methodological aspects 
as well as SERTs’ association to BN and acquired obesity in young adults.   
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2. REVIEW OF THE LITERATURE 
 
2.1 SEROTONIN (5-HT) 
2.1.1. Overview 
Serotonin (5-hydroxytryptamine, 5-HT), is one of the brain neurotransmitters. It 
belongs to the group of biogenic amine neurotransmitters, including also the 
catecholamines dopamine (DA), epinephrine (E) and norepinephrine (NE). However, 5-
HT also exists and has functions outside the central nervous system (CNS), e.g., in the 
gastrointestinal system, platelets and mast cells. The greatest concentration of 5-HT 
(approximately 90 %) is found in the gastrointestinal system, and only 1-2 % of the 5-
HT is found from the CNS (24). It was discovered in the early 1930’s from the rabbit 
gastric mucosa and named enteramine, and later on isolated and thereafter named as 
serotonin in 1948. The name serotonin originates from its initial discovery as a 
vasoconstrictor substance in blood serum. It was established as a neurotransmitter in the 
early 1950’s, and its role in the brain development and mental illnesses was suggested 
in the 1950’s and 1960’s (12). 
 
The importance of 5-HT as a neurotransmitter is highlighted by the fact that it has 
the highest number, altogether 14, of receptors of any of the neurotransmitters (25). 5-
HT regulates the homeostasis of many systems important for life, e.g., body 
temperature, appetite, sexual drive, sleep and circadian rhythms. Furthermore, 5-HT is 
known to modulate emotion, cognition, motor function and pain sensitivity. In addition 
to its role as a neurotransmitter, 5-HT has an important role in the development of 
neural system.  Pharmacological and molecular genetic studies have shown that during 
gestation and infancy 5-HT can modulate a number of developmental processes, 
including neurogenesis, axon branching, dendritogenesis and apoptosis (2). 5-HT also 
has demonstrable effects on synaptic plasticity and adult neurogenesis (3,26,27). 
Furthermore, disturbance of 5-HT function has been implicated in many psychiatric 
disorders including e.g., major depressive disorder (MDD) (5), anxiety (4), Anorexia 
and Bulimia Nervosa (6), obsessive compulsive disease (7), autism (28), and 
impulsivity and aggression (8,9).  
 
2.1.2. 5-HT synthesis and degradation 
5-HT consists of a five member ring containing nitrogen joined to a benzene ring. It is 
synthesized from the essential amino acid tryptophan (TRP), derived primarily from the 
diet. Both TRP and 5-HT belong to a group of aromatic compounds called the indoles 
(24).  
 
5-HT does not cross the blood brain barrier, hence it must be synthesized in the 
CNS. Both TRP and its next derivative before 5-HT, 5-hydroxytryptophan (5-HTP), 
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can cross this barrier. TRP is transported across the blood brain barrier by an active 
uptake process performed by the large neutral amino acid carrier. Not only TRP uses 
this transport mechanism, but also other large amino acids, e.g., tyrosine, 
phenylalanine, leucine, isoleucine and valine, compete for the same transport process. 
Therefore, not only the plasma concentration of TRP, but also its ratio to other 
competing large amino acids, affects the amount of TRP in brain. Nevertheless, the 
carbohydrate and protein content of the diet affect the plasma TRP concentration and 
have an effect on the 5-HT synthesis in the brain. The plasma TRP level has circadian 
rhythmic variation, which probably leads to some circadian variation also in the 5-HT 
synthesis. (24). 
 
Two enzymatic steps are needed for the synthesis of 5-HT from TRP. Firstly, TRP 
is oxidized to 5-hydroxytryptophan (5-HTP) by the enzyme tryptophan hydroxylase. 
Secondly, 5-HTR is decarboxylated by the enzyme 5-hydroxytryptophan decarboxylase 
to yield 5-HT (24). The oxidation of TRP by TRP-hydroxylase is the rate limiting step 
of 5-HT synthesis. The activity of TRP-hydroxylase is affected by the amount of its 
substrate TRP as well as by the amount of available oxygen, as TRP-hydroxylase 
requires oxygen to function. The end product of the enzymatic step, 5-HTP, does not 
affect the activity of TRP-hydroxylase, neither does the amount of 5-HT nor the 
metabolic end product of 5-HT’s catabolism, 5-hydroxyindolacetic acid (5-HIIA). On 
the other hand, the activity of 5-HT neurons can affect the functional capacity of TRP-
hydroxylase, serving as an autoregulative factor (24). Pharmacologic inhibition of TRP-
hydroxylase (e.g., by p-chlorophenylalanine) reduces the brain 5-HT content by 80 %.  
 
The catabolism of 5-HT also requires two steps and enzymes. After being reuptaken 
from the extracellular space into the presynaptic terminal by the serotonin transporter 
(SERT), 5-HT can be deaminated by the enzyme monoamine oxidase (MAO), yielding 
5-hydroxyindoleacetaldehyde. This can be further oxidized by the enzyme acetaldehyde 
hydrogenase to 5-HIAA or reduced to 5-hydroxytryptophol (24).  
 
2.1.3. 5-HT neurons  
A simplified illustration of the serotonergic pathways is depicted in Figure 1. The 
nuclei of the serotonergic neurons are mainly located along the midline of the brainstem 
from the midbrain to the medulla. The shared name, raphe, for the nuclei, is derived 
from this midline location (raphe, French for seam). Altogether nine raphe nuclei, 
numbered B1-9, have been described. The nuclei in the midbrain and pons (B4-9), 
including the dorsal, median and pontine raphe nuclei, project to the upper brainstem, 
hypothalamus, thalamus, and cerebral cortex. The nuclei in the medulla (B1-3), 
corresponding to the raphe magnus, raphe pallidus and raphe obscurus, project to the 
lower brainstem and the spinal cord. The rostral nuclei participate in regulation of the 
sleep-wake cycles, affective behavior, food intake, thermoregulation, and sexual 
behavior. The neurons in the lower pons and medulla participate in regulating the 
perception of pain and the tone in motor systems (1). Some serotonergic cell bodies can 
be found also outside the raphe nuclei, and not all cell bodies in the raphe nuclei are 
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serotonergic (29). For the forebrain functions, the dorsal (B6-B7) and median raphe 
(B8-B9) nuclei in the midbrain are most important. There are functional and 
morphologic differences between the serotonergic and non-serotonergic neurons of 
these two nuclei groups (29), and afferent connections exist between them. In the dorsal 
raphe, there are dendro-dendritic synaptic contacts between the serotonergic neurons, 
suggesting local autoregulatory interaction between the neurons. The dorsal and median 
raphe nuclei also get afferents from other cell body groups in the brainstem, such as the 
substantia nigra and ventral tegmental area (dopamine), superior vestibular nucleus 
(acetylcholine), locus coerulus (norepinephrine), nucleus prepositus hypoglossi and 
nucleus of the solitary tract (epinephrine). Other afferents include neurons from the 
hypothalamus, cortex and the limbic forebrain structures, e.g., amygdala (29).  
 
 
Figure 1. The serotonergic pathways 
 
2.1.4. 5-HT receptors  
There are at least 14 different 5-HT receptors in seven receptor subclasses (Table 1). 
While all receptor subtypes are found postsynaptically, 5-HT1A and 5-HT1B are also 
found on presynaptic cell bodies and dendrites, where they function as autoreceptors 
(30).  
 
Except for the 5-HT3 receptor subtype, which is a cation channel, all other 5-HT 
receptors are heptahelical transmembrane proteins that exert their action through G-
proteins on second messenger systems. The 5-HT1 subclass, 5-HT4, 5-HT5, 5-HT6 and 
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5-HT7 all act through the adenyl cyclase – cyclic adenosine monophosphate (cAMP) 
pathway. The receptors of the 5-HT1 subclass (A, B, D, E and F) inhibit adenyl cyclase, 
reducing the intracellular cAMP. 5-HT4, 5-HT6 and 5-HT7 receptors cause activation of 
adenyl cyclase and increase in the intracellular cAMP. The 5-HT5 receptors have been 
shown to cause both inhibition and activation of adenyl cyclase. The cAMP molecules 
cause activation of protein kinase A, which in turn activates other important signalling 
molecules. 5-HT2 subclass (A, B and C) receptors have second messenger systems 
operating through phospholipase C, causing formation of inositol-tris-phosphate (IP3) 
and diacylglycerol (DAG). IP3 binds to a receptor on the endoplasmic reticulum, 
triggering it to release Ca2+. The released Ca2+ and DAG then cause stimulation of the 
protein kinase C, which can lead to phosphorylation of the receptors (altering the 
properties of the G-proteins) or activation of transcription factors. The Ca2+ released 
from the endoplasmic reticulum can also stimulate the firing of neurons, lead to 
activation of K-channels antagonizing the effects of Ca2+, and lead to activation of 
tyrosine kinase - the mitogen activated protein kinase (MAPK) pathway activating 
many transcription factors (30).  
 
5-HT can act as a classical neurotransmitter (strictly in the synaptic cleft, between 
the presynaptic axon and postsynaptic neurons). However, in many sites it acts through 
volume (also known as paracrine or diffuse) transmission, by diffusing to more remote 
receptor sites. 5-HT1A, 5-HT1B auto- and heteroreceptors as well as 5-HT2A 
heteroreceptors receive their serotonergic input mainly by volume transmission (29).  
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Table 1. The 5-HT receptor subtypes. 
Subtype Type Signal 
transduction 
Localization Function 
5-HT1A GBR Inhibition of AC Raphe nuclei 
Hippocampus, cortex, 
septum 
Autoreceptor  
Postsynaptic heteroreceptor 
Modulates anxiety and 
depression? 
5-HT1B GBR Inhibition of AC Subiculum 
Substantia nigra, cerebral 
vasculature, trigeminal 
ganglion 
Autoreceptor and 
postsynaptic heteroreceptor 
Modulation of locomotor 
activity and aggression? 
Vasoconstriction 
5-HT1D GBR Inhibition of AC Cerebral vasculature,  
trigeminal ganglion 
Vasoconstriction 
5-HT1E GBR Inhibition of AC Entorhinal cortex, striatum  
5-HT1F GBR Inhibition of AC Dorsal raphe, hippocampus, 
cortex, striatum, cerebral 
vasculature, trigeminal 
ganglion 
Periphery 
Vasoconstriction 
5-HT2A GBR Activation of 
PLC 
Cerebral cortex  
Platelets, smooth muscle 
 
Neuronal excitation  
Modulates cognitive process 
of working memory?  
Platelet aggregation  
5-HT2B GBR Activation of 
PLC 
Stomach fundus Contraction 
5-HT2C GBR Activation of 
PLC 
Hippocampus, prefrontal 
cortex, amygdala, striatum, 
hypothalamus, choroid 
plexus 
Regulation of neuronal 
excitability 
Anorexigenic effects 
Anxiolytic effects? 
5-HT3 Ion 
channel 
 Area postrema, 
hippocampus, neocortex, 
amygdala, hypothalamus  
Peripheral nerves 
Pituitary gland, enteric 
nervous system 
Neuronal excitation, emesis 
5-HT4 GBR Activation of AC Hippocampus, striatum, 
substantia nigra, superior 
colliculus 
GI tract 
Neuronal excitation 
Modulation of 
neurotransmitter release (5-
HT, DA, ACh) 
Serotonergic regulation of 
cognition and anxiety? 
5-HT5A GBR Inhibition of AC Hippocampus, neocortex, 
cerebellum, raphe nuclei 
Unknown 
5-HT5B GBR Unknown Hippocampus, neocortex, 
cerebellum, raphe nuclei 
Unknown 
5-HT6 GBR Activation of AC Neocortex, hippocampus, 
striatum, amygdala 
Unknown 
5-HT7 GBR Activation of AC Hypothalamus, thalamus 
Intestine 
Modulation of circadian 
rhythms? 
GBR= G-protein coupled; AC= adenyl cyclase; PLC= phospholipase C 
(31,32) 
 
2.1.5. The serotonin transporter 
The serotonin transporter is reviewed in detail in section 2.2. 
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2.2. THE SEROTONIN TRANSPORTER (SERT) 
2.2.1. Overview 
The 5-HT signalling can be controlled by alterations in its synthesis, storage, release 
and inactivation. Inactivation of 5-HT is accomplished by the serotonin transporter 
(SERT, also known as 5-HTT and SLC6A4), which has an important role in controlling 
the amount of effective 5-HT in the extracellular space in the sites where 5-HT acts, 
e.g., the CNS, platelets, enterochromaffin cells, etc. In the CNS, SERTs terminate the 
action of 5-HT by removing it from the synaptic cleft or other extracellular sites, and 
returning it to the presynaptic neuron to be either recycled for use, or degraded by the 
MAO enzyme. By reuptake, SERT minimizes the duration of the neurotransmitter-
receptor interaction, and makes receptor desensitization less likely to occur. In the 
CNS, most of the SERTs (90 % in the rat) are located in the 5-HT neurons, and smaller 
amount in non-5-HT neurons (33).  
 
The natural endogenous substrate for SERT is 5-HT, and synthetic substrates 
include amphetamine and fenfluramine. Given the abundance of important processes 
that 5-HT modulates, it is logical that pharmacological antagonists for SERT have been 
developed. Tricyclic antidepressants (e.g., imipramine, clomipramine and amitriptyline) 
were the first SERT antagonists used; however, in addition to SERT, they bind also to 
norepinephrine transporters (NETs) and to a smaller degree also to dopamine 
transporters (DATs), and have problematic side effects. Also the abused drugs 
amphetamine, cocaine and ecstasy (MDMA) block all the monoamine neurotransmitter 
transporters. The selective serotonin reuptake inhibitors (SSRIs) block selectively 
SERTs and include drugs such as fluoxetine, sertraline and citalopram. While tricyclic 
antidepressants are sometimes still used in the treatment of depression, SSRIs have 
become more popular due to having less side effects and better safety profile. SSRIs are 
widely used in psychiatry; not only in the treatment of depression, but also of eating 
disorders, anxiety and obsessive-compulsive disease (10). Due to their effect on feeding 
behaviour, they also have some use as anti-obesity drugs (11).   
 
The gene coding for SERT belongs to the SLC6 neurotransmitter transporter gene 
family. This gene family also contains transporters for dopamine (DA), norepinephrine 
(NE), GABA, glycine, and for some amino acids, as well as some transporters with 
unknown substrates (orphan transporters). These transporters share several structural 
similarities. All are comprised of a single subunit with amino- and carboxyl termini, 
have 12 plasma membrane spanning regions, and have a large extracellular loop 
between the 3rd and 4th transmembrane regions. The intracellular parts of these 
transporters possess several phosphorylation sites, suggesting that second messengers 
regulate transporter function and subcellular redistribution (34). These transporters are 
also functionally similar; they all couple the uptake of their respective substrates to the 
co-transport of Na+ and Cl- ions and counter-transport of K+ to the extracellular space. 
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This transport process is dependent on maintenance of ion gradients across the cell 
membrane by Na+K+ATPases (35). 
 
The functional role of the SERTs has been studied using SERT knockout mice 
(mice devoid of SERTs). These mice show increased extracellular 5-HT levels (36), 
decreased whole brain tissue 5-HT levels (37), increased 5-HT synthesis (37), down-
regulation of the function of 5-HT1A and 5-HT1B receptors (38) and no alterations in the 
other neurotransmitter systems (39). The SERT knockout mice also display several 
behavioral phenotypes, e.g., depression-like symptoms (40) and reduced aggression 
(41). However, these results cannot be directly applied on humans, as variations in 
SERT activity are more subtle and the causal relationships less well known. 
 
2.2.2. Genetic variation of gene coding for SERT 
The gene coding for the serotonin transporter (SLC6A4) is located in the chromosome 
17q11.2. It consists of 14 exons and spans 37.8 kb, and encodes a 630 amino acid 
protein (42). Given that SERT is a key regulator of the bioavailability of 5-HT and the 
wide spectrum of functions and behaviors that 5-HT affects, any modulation in the 
expression or action of 5-HT would be expected to have consequences (43).  
 
Polymorphic areas have been found both from the coding and the non-coding 
sequences of the SERT gene. In the coding sequences, some regions with single 
nucleotide polymorphism (SNP) are known; however, none of them has been found to 
associate with clinical disorders thus far (43). In contrast, the non-coding sequences are 
known to have regions with variable number tandem repeat (VNTR) polymorphism, 
and these polymorphisms have been associated with a predisposition to various 
psychiatric and neurological disorders. While polymorphism in the non-coding 
sequences has no effect on the structure of the coded protein, it can affect the amount of  
expression of the protein or the post-transcriptional properties of the gene, such as 
mRNA stability. It has been suggested that the VNTR regions act as both tissue-
specific and stimulus-inducible regulators of SERT gene expression. They may fine-
tune SERT function by altering the level of transporter mRNA, which in turn regulates 
the concentration of SERT in specific cells or in response to chemical, physiological or 
environmental challenges (43). It has been suggested that this kind of modulation of 
gene expression, altering neurotransmitter signalling in response to various challenges 
and stresses, may be correlated not only with a predisposition to various disorders but 
also to the variation between individuals (43). In an individual suffering of a specific 
disorder, e.g., major depression, SERT polymorphism may also affect the 
pharmacological response to SSRI treatment (44). The differential SERT expression 
caused by SERT polymorphism may also affect 5-HT levels during embryogenesis and 
early life (45). This may have long-standing implications, as temporary alterations in 5-
HT homeostasis during development may modify the fine-wiring of brain connections 
and lead to permanent changes in adult behavior (2,46). 
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At present, several polymorphic regions are known in the SERT gene. Most 
investigated to date is the biallelic insertion/deletion found in the 5´ promoter region of 
the gene 1.2 kb upstream of the start of the transcriptional site (47,48). This VNTR is 
called 5-HTT gene-linked polymorphic region (5-HTTLPR), and was initially 
identified as two variants containing either 14 (deletion/short, abbreviated as “S”) or 16 
(insertion/long, abbreviated as “L”) copies of a 22 bp repeat. An individual can be 
homozygous (LL or SS) or heterozygous (LS) for these alleles. Many studies have 
found the level of SERT expression to be higher in the LL homozygotes as compared to 
carriers of one or two S alleles (48-50); dominant effect of the S allele has been 
suggested by some (48,49), while other studies have suggested an additive, not 
dominant effect of the 5-HTTLPR polymorphism (50). Further subgroups were later 
found to exist in this VNTR to give rise to altogether fourteen allelic variations of the 
region (51). One of these, a SNP with A to G substitution of the long variant (rs25531), 
has attracted more interest than others. Some studies have suggested that this LG variant 
may be similar to S allele in causing reduced SERT mRNA levels as compared to LALA 
homozygotes (52). However, only some of the most recent studies on 5-HTTLPR 
polymorphism have taken this SNP into account.  
 
Association studies on 5-HTTLPR polymorphism have found increased risk of 
several psychiatric disorders in connection to the 5-HTTLPR variants. SS-
homozygosity has been associated with increased risk to uni- and bipolar depression 
(53-55), anxiety (49,56,57), and predisposition to depression and suicide following 
stressful life-events (58,59). LL-homozygocity has been associated with increased risk 
of OCD (60) and increased intensity of hallucinations in schizophrenic persons (61). 
Structural and functional brain differences have also been reported between healthy 
carriers of the different 5-HTTLPR variants. As compared to LL-homozygotes, the 
carriers of S allele have been reported to have reduced volume and grey matter density 
in several frontal regions, and increased reactivity (as studied with fMRI) to both 
negative (in striatum and insula) and positive (in left frontal and posterior cingulated 
regions) stimuli (62). Increased amygdala reactivity to fearful stimuli is a very 
consistent finding in carriers of S allele (63-66), but has recently been suggested to 
result from reduced activation in response to neutral stimuli rather than from increased 
reactivity to fearful stimuli (62). Also the “functional connectivity” of amygdala with 
ventromedial prefrontal cortex (66) and perigenual anterior cingulate cortex (67) has 
been reported to differ between the 5-HTTLPR variants. It has been suggested that 5-
HTTLPR genotype is a susceptibility factor for affective disorders by biasing the 
functional reactivity of the human amygdala in the context of stressful life experiences 
(64).  
 
Studies done in rhesus monkeys, which have a polymorphism in the promoter 
region of 5-HTT gene functionally similar to human 5-HTTLPR polymorphism, have 
given light to the gene x environment interaction in association of this polymorphism. 
Several studies have suggested that carriers of the S allele are more vulnerable to 
stressful life events (being reared by peers instead of their mothers) in early life, leading 
to far reaching consequences such as aggressiveness (68) and higher use of alcohol and 
greater sensitivity to its effects (69,70). These monkeys also show lower CNS 5-HT 
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turnover (71). Human studies likewise have shown gene x environment effects of 5-
HTTLPR polymorphism. Carriers of the S-allele who are exposed to childhood 
maltreatment or stressful life-events are more vulnerable to adult depression than LL 
homozygotes (58).  
 
Several PET and SPET studies have been published on the effect of the 5-HTTLPR 
genotype on the brain SERT binding, but their results have been inconsistent. The first 
published study on this field used [123I]-β-CIT as its ligand and reported elevated 
brainstem SERT binding in LL homozygotes as compared to S carriers (72), but later 
studies using the same ligand did not replicate this finding (73,74). A PET study using 
[11C]-McN5652 as a ligand found also no difference in SERT binding between the 
genotypes (75). Three PET studies on 5-HTTLPR polymorphism grouped the L alleles 
further into LA and LG. A study using [11C]-McN5652 found no differences between 
genotypes (76), whereas two studies using [11C]-DASB found elevated SERT binding 
in LALA carriers compared to carriers of S or LG in the putamen (77) and the midbrain 
(78). 
 
A second widely studied VNTR in the non-coding region of the SERT gene is 
called STIN2. It is located in intron 2 and can have 9 (STin2.9), 10 (STin2.10) or 12 
(STin2.12) copies of a repeat sequence (79), giving rise to six possible genotypes. Also 
STIN2 VNTR can lead to differential levels of SERT expression, the STin2.12 having 
the greatest enhancing effect on the SERT expression (80). Despite somewhat 
discrepant results, association studies have linked also this polymorphism to a number 
of psychiatric and neurological disorders, e.g., STin2.9 allele to mood disorders 
(79,81), anxiety (82), and migraine with aura (83); ST2in2.12 to OCD (84) and 
migraine without aura (83); and STin2.10 homozygosity to predisposition to suicide 
(85).  No brain imaging studies have been published to date on the effects of the STIN2 
polymorphism. 
 
2.2.3. Regulation of the SERTs 
Like other Na+/Cl- -dependent neurotransmitter transporters, also SERTs can be 
regulated both long-term (regulation at the gene level, on a timescale of days) and 
short-term (regulation at the protein level, on a timescale of seconds to minutes). Both 
long- and short term regulation can affect either transporter activity, transporter number 
on the cell membrane, or both (34). A lot has been discovered about the signalling 
mechanisms involved, especially in the acute regulation; less is still known about the 
factors that trigger these regulatory changes in the gene and protein level. 
 
2.2.3.1. Short-term regulation 
There are two different modes for short-term regulation of SERTs: regulation of the 
number of SERTs expressed on the plasma membrane (“trafficking-dependent 
regulation”) and regulation of the SERTs’ intrinsic activity (“trafficking-independent 
regulation”) (86). The term “trafficking“ is used when discussing SERT internalization 
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from the plasma membrane to the cytosol and externalization from the cytosol to the 
plasma membrane. For the regulation of the amount of effective 5-HT in the synaptic 
cleft and on other extracellular sites, only the amount of SERTs on the plasma 
membrane matters, not the total number of SERTs in the neuron (including SERTs in 
the cytosol as well as on the membrane). In the trafficking-independent regulation, the 
SERT activity is altered independent of changes in SERT density.   
 
At present, less is known about the factors that trigger acute regulation at the protein 
level than about the following signalling mechanisms. Nevertheless, it has been shown 
that at least the following factors can trigger alterations in the status of the Na+/Cl- -
dependent neurotransmitter transporters: 
1. Transient changes in the membrane potential; depolarization is associated with 
reduced 5-HT uptake and hyperpolarization with enhanced uptake (87,88). 
2. Occupancy of SERT by its substrate or inhibitor; 5-HT and the pharmacological 
substrates amphetamine and fenfluramine prevent SERT internalization, whereas 
SERT inhibitors SSRIs and cocaine prevent the effect of substrates (89). 
3. Ethanol; enhances SERTs’ activity (90). 
4. Presynaptic autoreceptors; 5-HT1B activity has been suggested to increase SERT 
activity (91). 
5. Presynaptic heteroreceptors; for example stimulation of Alpha-2 adrenergic 
heteroreceptors has been shown to lead to a rapid down-regulation of SERT 
activity (92). 
 
The signalling mechanisms for acute regulation are complex and not fully 
understood. For the trafficking-dependent regulation, best studied are the different 
protein kinases and phosphatases that act by affecting SERT’s phosphorylation status 
(34). The phosphorylation of SERT by activation of protein kinase C or inhibition of 
protein phosphatases 1 and 2A leads to internalization of SERTs and thereby decreases 
SERT density on the plasma membrane (93,94). One mechanism through which this is 
achieved is disruption of SERTs association with protein phosphatase 2A (PP2A) on 
the plasma membrane (95). Further trafficking-dependent mechanisms reducing SERT 
activity include SERTs association with neuronal nitric oxide synthase (nNOS) (96), 
and α2-adrenergic receptor (α2AR) activation (92), which both may contribute to SERT 
internalization. The p38 mitogen-activated protein kinase (p38 MAPK) is also involved 
in maintaining the basal phosphorylation of SERT, and its inhibition leads to reduced 
SERT insertion to the plasma membrane and thus reduced 5-HT uptake (97). SERT 
externalization leading to increased SERT densities may be achieved by activation of 
A3 adenosine receptor (A3AR), requiring protein kinase G (PKG) activation by a 
phospholipase C, Ca++, and cGMP-dependent mechanisms (86,98,99).  
 
Trafficking-independent elevation of SERT activity can be achieved by PKG 
activation (100), or by activation of p38 MAPK (101). p38 MAPK activation can be 
stimulated either by PKG or directly independent of PKG by inflammatory cytokines 
interleukin-1beta (IL-1beta) and tumor necrosis factor alpha (TNF-alpha) (102). 
Trafficking-independent reduction in SERT activity can be achieved by PKC activators 
(103). 
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2.2.3.2. Long-term regulation  
Long-term regulation can be caused by physiological changes (for example in age and 
hormonal status) and gene-environment interactions. Also pharmacological agents, with 
chronic administration of substrates and antagonists of SERT as well as abused 
substances such as cigarettes, ethanol and abused drugs may cause long term changes in 
SERTs. The effects of pharmacological agents are easiest to study in experimental 
settings, and thus more is known about them than other factors. The long-term 
regulation of SERTs is thought to involve changes in gene transcription and mRNA 
translation/stability, but post-translational modifications, protein trafficking, 
cytoskeleton interactions and oligomerization may be involved, too (34). The SERT 
gene possesses binding sites for several transcription factors (104).  
 
2.2.3.3. Factors that may cause long-term regulation of SERTs 
Due to extensiveness of this field of study only areas relevant for SERT imaging will be 
reviewed.  
  
2.2.3.3.1. Chronic drug administration  
Studies with chronic SSRI treatment show down-regulation of SERTs (105,106). 
 
2.2.3.3.2. Aging 
Post mortem studies on the effect of healthy aging on SERT densities have had 
discrepant results (107-109). Radioligand binding studies by SPET and PET on healthy 
humans have most often reported 2-10% decline in SERT binding per decade (110-
115), even though some studies show no effect of age (116-118).   
  
2.2.3.3.3. Gender and sex steroids  
A large body of data indicates sexual dimorphism in various aspects of the 5-HT 
system. Sexual dimorphism is also present in the prevalence of psychiatric disorders 
associated to disturbed 5-HT function, e.g. major depression (119).  
 
Sex steroid effects have been studied in animal models, and these results vary 
slightly depending on the species studied. Receptors for 17β-estradiol (17β-E), 
progesterone (P) and androgens are found in the serotonergic dorsal raphe nuclei of 
mice, rats (120,121) and primates (122,123). Both ovarian hormones and testosterone 
seem to affect the serotonergic system. Male rats have higher basal tonic firing activity 
of serotonergic neurons in the dorsal raphe than female rats (124), and in female rats, 
this basal firing rate is higher during pregnancy and the postpartum period (124). Both 
testosterone and 17β-E increase the basal firing rate of the 5-HT neurons both in male 
and female rats (125), and metabolites of progesterone increase the basal 5-HT firing 
rate in female rats (126). Ovarian steroids have also been shown to modulate the 
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expression of different genes of the 5-HT system, increasing tryptophan hydroxylase 
mRNA (127) and reducing 5-HT1A mRNA (128). Regarding the expression of SERTs, 
some discrepancy exists depending on the species studied; in ovariectomized monkeys, 
ovarian steroids reduced SERT mRNA (129), while in ovariectomized and castrated 
rats estradiol and testosterone increased SERT mRNA (130,131).   
 
Human studies show that women as compared to men have higher blood 5-HT 
levels but lower 5-HIAA levels (132). Women also have lower rate of serotonin 
synthesis, as studied with α-[11C]methyl-L-tryptophan and PET (133,134). The rate of 
5-HT synthesis is also reduced more in women than in men as a consequence of acute 
tryptophan depletion (ATD) (133). Also the mood effects produced by ATD are 
stronger in women than in men (135).  
 
Sex differences in the human brain SERT binding have been investigated by two 
SPET and PET studies, one reporting higher SERT binding in men (136) and the other 
in women (137). Women are reported to have higher availability of 5-HT1A receptors in 
several brain areas (137-139). While some studies have found no effect of sex on the 
brain 5-HT2A binding (140,141), other studies have reported an increase of 5-HT2A 
binding in postmenopausal women following treatment with estradiol and progesterone 
(142,143).  
 
Given that sex steroids seem to affect the 5-HT system, it is also possible that 
fluctuation of the levels of ovarian hormones during menstrual cycle causes alterations 
in the 5-HT system. Cyclic alterations of hypothalamic 5-HT levels (144,145) and 5-
HT1A binding (146) have been reported in rodents. In humans, such alterations have 
been reported in platelet 5-HT2A binding (147), whereas results regarding the blood 5-
HT levels (148,149) and platelet SERT binding (147,150) are discrepant. A recent PET 
study on 5 healthy women reported higher 5-HT1A binding in the dorsal raphe in 
follicular as compared to luteal phase (151). The only study to date to investigate the 
within-subject variation in the brain SERT binding between luteal and follicular 
menstrual phases of healthy women did not detect significant variation in the region 
investigated (diencephalon-brainstem) (152).  
 
2.2.3.3.4. Seasons and the amount of light 
Variation of 5-HT function has been suggested as a consequence of day-to-day 
variation in the amount of sunlight (153) and variation of seasons (153,154). 
Hyposerotonergic state during the dark season has also been proposed as one etiologic 
factor in the Seasonal Depressive Disorder (SAD) (155,156). Studies investigating 
seasonal variation of 5-HT indices in healthy humans have had inconsistent results. The 
first study on this topic investigated post mortem human brains and reported seasonal 
variation in the hypothalamic 5-HT levels, with a maximum during fall and minimum 
in winter (154). Since then, other studies have investigated 5-HT indices in healthy 
living subjects. Studies on CSF and internal jugular vein 5-HIAA levels have suggested 
increased turnover of 5-HT in summer (153,157), whereas studies on platelet SERT 
binding have had inconsistent results, reporting either higher (158) or lower (159) 
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SERT densities in summer than in winter, or no circannual variation (160). Similar 
inconsistency applies to results of platelet 5-HT2A binding studies (158,161,162) and 
neuroendocrine challenge tests (163). Only one prior imaging study has investigated 
seasonal variation in the central 5-HT system; this SPET study reported higher SERT 
binding in women investigated in summer as compared to different women investigated 
in winter (164).  
 
2.2.3.3.5. Tobacco, alcohol and drugs of abuse  
In animal studies, nicotine increases brain 5-HT release (165), which by activation of 5-
HT1A receptors leads to transient, short-term inhibition of the serotonergic neurons in 
the dorsal raphe nucleus (166). Nicotine also affects the brain [3H]paroxetine binding in 
a region-specific manner (167).  Studies on the effect of cigarette smoking on the 5-HT 
system in humans are scant. One SPET study reported modestly higher (10%) SERT 
binding in the brainstem of smokers as compared to non-smokers (136). No other SPET 
or PET studies have been published on the effect of cigarette smoking on the brain 5-
HT system. 
 
Three studies have compared SERT binding of alcoholic subjects to that of healthy 
controls, reporting either decreased binding in the midbrain (168) and the brainstem 
(116), or no differences (169) between alcoholic and non-alcoholic subjects. No 
imaging studies have been published on the effect of social drinking on SERT binding. 
 
Of the drugs of abuse, the effect of MDMA on the brain SERT binding has been 
investigated in several studies. At least two human studies have reported reduced SERT 
binding in the MDMA users (170,171), whereas a recent study examining baboons did 
not find differences between MDMA users and controls (172). The same study also 
reported increased SERT binding in cocaine-abusing baboons.  In humans, PET or 
SPET studies investigating the effect of the drugs of abuse other than MDMA on the 5-
HT system have not been published.   
 
2.3. IMAGING OF THE BRAIN 5-HT SYSTEM 
2.3.1 Emission tomography methods 
2.3.1.1 Overview 
The techniques for brain imaging applying radioactive ligands include single photon 
emission tomography (SPET) and positron emission tomography (PET). While both 
apply radioactive isotopes for non-invasive in vivo imaging, these methods differ with 
respect to the used radioactive isotopes, machinery, and image resolution.  
 
Isotopes are different forms of an element, each having the same number of protons 
(the same atomic number) but different number of neutrons (different mass number), 
which makes the nucleus unstable. The unstable nucleus has excessive energy which is 
released in radioactive decay. In this process, the excess energy is emitted as newly-
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created radiation particles (α, β+, and β-particles being the most common ones), or as 
electromagnetic waves (γ- or x-rays) (173).  
 
Some radioactive isotopes occur naturally, and others are produced artificially. The 
radioisotopes used in SPET emit gamma rays, and are typically derived from the 
naturally occurring forms of an element rather easily. PET studies use positron emitters, 
which are always artificially produced. This is usually done in a cyclotron, although in 
future generators may be used increasingly for production of some positron emitters. 
The most common isotopes used in SPET are 99mTc and 123I, while in PET most 
common are 11C, 15H, 18F and 68Ga. In both emission tomography methods, the 
radioactive isotope is combined to a pharmaceutical agent, thus forming a radioligand. 
It is usually given to the study subject as an intra venous injection. In the body, the 
radioligand is typically incorporated into a metabolic process or binds to a specific 
receptor, enabling imaging of specific molecules or metabolic processes (173). 
 
Until recently, use of SPET has been considerably more common than PET, but 
recent rapid spread of PET machinery as well as the development of suitable ligands 
have shifted the emphasis to PET studies. SPET has the advantage of cheaper 
machinery and more easily available radioligands, while isotopes used in PET typically 
require a cyclotron in vicinity of the scanner for their production. However, positron 
emitters can be incorporated to virtually all organic compounds and thus allow wider 
range of targets. Also the imaging resolution achieved with PET (typically 5-7 mm) is 
superior to SPET (typically 10-14 mm).  
 
2.3.1.2. Principles of SPET  
As mentioned above, radioisotopes emitting gamma rays are used in SPET studies. The 
radioligand given to the study subject binds to its target sites in the body and emits 
gamma rays. These are detected by crystal planes (detectors) of the gamma camera, 
which absorb the gamma rays and scintillate in response to detected gamma radiation. 
The scintillation is detected by photomultiplier tubes, which transform the light photons 
to an electric signal, which is reconstructed into two-dimensional images by computer 
systems. This reconstructed image reflects the distribution and relative concentration of 
radioactivity in the organs and tissues imaged. In SPET imaging, the gamma camera 
acquires two-dimensional images from multiple angles, and computer systems 
reconstruct three-dimensional images from the two-dimensional ones (173). 
 
2.3.1.3. Principles of PET 
In PET studies, the radioactive nucleus of the radioligand emits positrons, which travel 
in tissue typically a distance of 1-2 mm before colliding to and combining with their 
counterparts electrons. This process is called annihilation, and in it the two particles 
vanish and are converted into energy in the form of two 512 keV gamma rays, which 
travel in opposite directions. These gamma rays are detected simultaneously by a ring 
consisting of several small gamma detectors and are then further processed into three 
dimensional images (173). 
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2.3.1.4. Quantification methods 
2.3.1.4.1. Tracer kinetic modelling 
Emission tomography scans measure total radioactivity in tissue. This consists not only 
of radioligand bound specifically to the target receptors, but also of free tissue activity 
(non-specific activity) as well as free radioactivity within vasculature. In order to 
compare the target receptors between subjects or groups, it is necessary to be able to 
make estimations of receptor-specific binding and for this tracer kinetic modelling is 
needed. These models describe the radioligands pharmacokinetics and rate constants for 
flux of the ligand between different compartments (Figure 2), and necessitate 
collection of kinetic data with input and output functions (174).  
 
 
Figure 2. Standard compartmental model for receptor-binding ligands. Ca, Cf, and Cb represent 
time-dependent local activity of radioligand in blood (Ca), free in tissue (Cf) and bound in tissue 
(Cb). k1 to k4 represent the rate constants between compartments.  
 
Full kinetic models involve serial measurements of concentration of the radioligand 
(corrected by its metabolites) from the plasma and dynamic/serial emission tomography 
scans for measurement of time-activity curves in a target regions. For derivation of 
receptor density (Bmax) and equilibrium dissociation constant (Kd) at least two studies at 
different specific activities are needed. Instead of Bmax and Kd, binding potential (BP = 
Bmax/Kd) is usually the parameter of interest in clinical studies comparing receptor-
specific binding between groups. In the absence of competing ligands, a modified 
binding potential BP´ can be calculated from the measured parameters of a kinetic 
study as BP´ = f2 Bmax/Kd = k3/k4, where f2 is the fraction of free ligand in tissue 
(174,175). This model assumes that non-specific binding in tissue is a constant and can 
thus be disregarded. 
 
Reference region approaches are simpler quantification methods that have been 
developed in order to avoid invasive full kinetic studies with arterial sampling. These 
methods compare radioactivity in a target region (containing the receptor of interest) to 
radioactivity in a reference region (devoid of specific receptor binding). Under 
equilibrium conditions the volumes of distribution can be obtained, usually by simple 
 25 
measurement of tissue activity in target and reference regions. The two regions should 
differ with respect to bound tracer CB but contain the same activity of free tracer CF. In 
this setting BP´ is related to the different distribution volumes in target (DVrec) and 
reference (DVref) tissues, and to the ratio between activities of the target (Ct) and 
reference (Cf) tissues, and can be expressed as: BP´= (DVrec/DVref)-1 = (Ct/Cf)-1 
(174,175). 
 
As actual equilibrium is often difficult to reach, an approximation using graphic 
presentation of kinetic data, the Logan plot (176) may be used. In this method, the 
integral of regional activity over current regional activity is plotted versus the integral of 
plasma activity over regional activity, and the slope of the curve approximates the 
regional tracer DV. In further simplification, arterial sampling can be substituted by 
deriving the input function from the time activity curve of the reference region. By 
comparing the slopes for the target (DVrec) and the reference region (DVref), the BP can 
be calculated as BP= (DVrec/DVref) – 1 = Distribution volume ratio (DVR) – 1 
(174,177). The assumption of this model is that the flux from the free tissue 
compartment to arterial plasma compartment (k2) remains constant in the target and 
reference regions.  
 
Due to the longer physical half lives of SPET ligands as compared to PET ligands, 
kinetic studies with measurement times over several hours are usually needed. These 
are not well tolerated by study subjects, and thus more patient-friendly methods with 
single scans are usually favoured. The most popular is the use of the simple ratio 
method, where the ratio of specific to unspecific binding is expressed as Specific 
binding ratio (SBR) = (mean counts in the target region- mean counts in the reference 
region)/ mean counts in the reference region. SBR is sometimes also called as Specific 
uptake ratio (SUR). 
 
2.3.1.4.2. Definition of target regions 
Brain studies applying emission tomography methods typically estimate radioligand 
binding in a predefined region or volume of interest (ROI or VOI), or alternatively, 
radioactivity can be assessed in each voxel.   
 
ROI (or VOI) based methods. If these methods are used, the regions of interests are 
decided on the basis of the prevailing knowledge about the distribution of the target 
receptor in the brain and on the functional relevance of these regions to the study 
questions. Careful selection of ROIs reduces the number of statistical analyses, thus 
increasing study power. Several methods are used in ROI definition. Some studies 
define their ROIs on the basis of anatomical boundaries given e.g., by an MR image 
(117,178) or the early phase radioligand image mimicking brain perfusion image (179). 
However, the limitation for using anatomical images for target region definition is the 
fact that many of the brain nuclei cannot be seen in the anatomical images. In this case 
a larger anatomical structure (containing also tissue other than the specific brain nuclei) 
may be selected for binding quantification. Alternatively, the ROIs can be placed 
directly on the SPET/PET images, where radioligand distribution shows the location of 
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the target sites. ROIs can then be either drawn manually based on the visual 
information provided by the image (180), or alternatively, fixed ROIs, e.g., of spheres 
with fixed area/volume can be placed over the predetermined brain regions (181).   
 
Voxel-based methods. These methods typically use brain templates generated 
specifically for the radioligand in question (182-184). Individual brain images are 
registered and realigned to the template, thus generating stereotactic images from the 
individual brain scans. The stereotactic brain images can then be used for estimation of 
radioligand binding in each voxel, enabling voxel-by-voxel comparisons between 
subjects and study groups. Some nuclear medicine workstations offer programs for 
formation of brain templates. During recent years, Statistical Parametric Mapping 
(SPM) (Wellcome Department of Imaging Neuroscience, UCL, London, UK) (185) has 
become a popular tool for voxel-by-voxel analyses of brain images generated by PET, 
SPET and MRI studies.  
 
2.3.2. Radioligands for imaging of the brain 5-HT system 
2.3.2.1. 5-HT synthesis and neuronal activity 
Two radioligands targeted to different steps in the 5-HT synthesis have been 
investigated as potential ligands for PET studies. 11C-labeled α-methyl-L-tryptophan 
(11C-αMtrp) (186) is an analog of tryptophan, which is a substrate for tryptophan 
hydroxylase, the first enzyme in the two-step synthesis of 5-HT. It is in part further 
metabolized into 11C-α-methyl-serotonin in 5-HT neurons. The second ligand, 5-
Hydroxy-L-[ -11C]tryptophan ([11C]HTP) is identical to the endogenous compound 
that will undergo conversion to 5-HT by aromatic L-amino acid decarboxylase, the 
second enzyme in the biosynthesis, and then further catabolism by MAO A enzyme to 
5-HIAA. These ligands have been studied in healthy subjects (133,134,187), and there 
are also few studies in patients (188-190). Some groups have investigated 5-HT 
neuronal activity indirectly, by measuring fenfluramine-induced changes in cerebral 
glucose metabolism with 18F-fluorodeoxyglucose (18FDG) and PET (191-193).  
 
2.3.2.2. 5-HT receptors 
Several radioligands exist for imaging of 5-HT2A receptors, e.g.  PET ligands 
[18F]Setoperone (194), [18F]altanserin (195) and [11C]MDL 100,907 (196), as well as 
SPET ligand 123I-R91150 (197). For 5-HT1A receptor imaging, [carbonyl-11C]WAY-
100635 (198) and [18F]MPPF (199,200) have been used in PET studies,  whereas no 
good SPET ligands for 5-HT1A imaging are available at the moment.  Both these 
receptors have been studied in patient samples, for example in major depression 
(201,202), schizophrenia (203) and eating disorders (204,205).   
 
2.3.2.3. Serotonin transporters 
In radionuclide imaging studies of the 5-HT system, serotonin transporters have been 
the most popular study object. This is perhaps due to existence of SERT ligands for 
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both SPET and PET imaging. Until the last couple of years, SERTs were mainly 
investigated using SPET. However, this is changing due to a rapid spread of PET 
machinery and development of SERT ligands for PET imaging.  
 
For years, most SERT studies were done using the SPET ligand [123I]methyl 3 beta- 
(4-iodophenyl) tropane-2 beta-carboxylate ([123I]β-CIT). The problem with [123I]β-CIT 
is that it is nonselective, i.e., has affinity for DATs, SERTs, and with a minor degree to 
NETs (206-209). Based on displacements studies, its binding in the striatum represents 
binding to DATs and binding in the thalamus and midbrain areas represents binding to 
SERTs (208,210). However, autoradiography studies show the existence of DATs (211) 
and NETs (212) in the midbrain and NETs in the thalamus (212). Furthermore, a PET 
study investigating non-human primates reported displacement of [11C]β-CIT by NET 
ligands in the thalamus (209). The results gathered from [123I]β-CIT studies may thus in 
theory be affected by binding to DATs and NETs also in the areas considered specific 
for SERT, i.e., the midbrain and thalamus. [123I]2beta-carbomethoxy-3beta-(4-
iodophenyl) [123I]nor-β-CIT is an analogue of [123I]β-beta-CIT with high affinity to 
both SERTs and DATs, but with tenfold higher affinity to SERTs in comparison to 
[123I]β-CIT (213). Similar to [123I]β-CIT, its binding to midbrain and thalamus is 
considered to be specific for SERTs (214,215); nevertheless, due to its non-selectivity, 
binding to other monoamine transporters remains a possibility also for [123I]nor-β-CIT.  
 
Iodine 123-labeled 2-((2-((dimethylamino)methyl)phenyl)thio)-5-iodophenylamine 
([123I]ADAM) is a newer SPET ligand that binds selectively to SERTs, having 10,000-
fold affinity for SERTs over DATs and NETs (216), and therefore its binding to other 
monoamine transporters is not a problem. Several groups have assessed its imaging 
characteristics in humans (217-223). However, also [123I]ADAM possesses some 
problems; the optimal scanning time varies somewhat depending on the density of 
SERTs in the region (217,223), and thus kinetics may vary between individuals and 
perhaps even more between  patients and healthy controls depending on their respective 
SERT densities. Its test-retest variability is not ideal, being 13% ± 11% in the midbrain, 
16% ± 13% in thalamus, and around 20% in the regions with lower SERT binding 
(217); this variability increases the  sample sizes that are needed to obtain significant 
results in clinical studies. Furthermore, according to recent report (223), the simple 
ratio method used for quantification of SERT binding by all previous studies applying 
[123I]ADAM may overestimate the specific binding values in high binding regions. Use 
of more reliable methods (Logan model) would require longer acquisition times (120 
min as compared to 30 min) (223) and may thus be impractical. 
 
To date, three PET ligands for SERT imaging have been used in clinical human 
studies: [11C]McN5652 (224), [11C]DASB (225), and [11C]MADAM (226). Of these, 
[11C]McN5652 has weaker specific-to-non-specific binding ratios than [11C]DASB 
(227), making it a less optimal tracer. [11C]DASB and [11C]MADAM both have mean 
test-retest difference less than 11 % in regions with high SERT densities (228-230), and 
the reported intra-class correlation coefficients (ICCs) for test-retest data are either 
acceptable (in raphe, due to large inter-subject variability) (228,230) or good (228-230). 
No test-retest data have been published on [11C]McN5652. [11C]McN5652 and 
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[11C]DASB have been used in patient samples, [11C]MADAM so far only in preclinical 
studies done in healthy subjects. 
 
2.4. BULIMIA NERVOSA 
2.4.1. Clinical characteristics and epidemiology 
Bulimia Nervosa (BN) is an eating disorder characterized by body image distortions 
and alternating episodes of binge eating and inappropriate compensatory behaviors. Its 
diagnostic criteria (DSM-IV) (231) are given in Table 2. Based on the individual’s 
compensatory behaviours, BN is further classified either as the purging subtype 
(including vomiting and misuse of laxatives, diuretics, or enemas) or non-purging 
subtype (including restricted eating and exercise).  
  
 
Table 2. DSM-IV criteria for Bulimia Nervosa 
 
DSM-IV Criteria for Bulimia Nervosa (307.51) 
A. Recurrent episodes of binge eating. An episode of binge eating is characterized by 
both of the following: 
(1) Eating, in a discrete period of time (e.g., within any 2-hour period), an amount of 
food that is definitely larger than most people would eat during a similar period of 
time and under similar circumstances 
(2) A sense of lack of control over eating during the episode (e.g., a feeling that one 
cannot stop eating or control what or how much one is eating) 
B. Recurrent inappropriate compensatory behavior in order to prevent weight gain, such 
as self-induced vomiting; misuse of laxatives, diuretics, enemas, or other medications; 
fasting or excessive exercise  
C. The binge eating and inappropriate compensatory behaviors both occur, on average, 
at least twice a week for 3 months 
D. Self-evaluation is unduly influenced by body shape and weight 
E. The disturbance does not occur exclusively during episodes of anorexia nervosa 
 
Specify type: 
Purging type: During the current episode of bulimia nervosa, the person has regularly 
engaged in self-induced vomiting or the misuse of laxatives, diuretics, or enemas 
Nonpurging type: During the current episode of bulimia nervosa, the person has used 
inappropriate compensatory behaviors, such as fasting or excessive exercise, but has not 
regularly engaged in self-induced vomiting or the misuse of laxatives, diuretics, or 
enemas 
(231) 
 
The lifetime prevalence of BN has been estimated to range from 1.1% to 4.6% (232-
234). It has been estimated that only a small minority (6%) of the BN patients are 
treated in mental health care (235).  
 
The onset of BN usually occurs in adolescence or early adulthood and is most 
frequently seen in women (13). Restrictive eating behavior often precedes the onset of 
BN, and about a quarter of BN patients have previously suffered from Anorexia 
Nervosa (236). Later on, dietary restriction is interrupted by episodes of binge eating 
(13). The disorder is often self-perpetuating, but 5–10 years later, between a quarter and 
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a half of individuals still have an eating disorder of clinical severity (234,237,238). 
Unlike Anorexia Nervosa, BN is not associated with increased mortality (16). 
Individuals with BN who engage in frequent vomiting may suffer from somatic 
problems such as electrolyte abnormalities, metabolic alkalosis, erosion of dental 
enamel, swelling of the parotid glands, and scars and calluses on the backs of their 
hands (239). Bulimia Nervosa patients also often suffer from other psychiatric 
morbidity at some point in their life. Common comorbid psychiatric conditions include 
e.g., major depression, substance and alcohol abuse, impulse control disorder, and 
personality disorders (240-242). Personality features of individuals with BN include 
some features shared with Anorexia Nervosa such as high harm avoidance, 
perfectionism, and low self-esteem. Features more specific to BN include higher 
novelty seeking, higher impulsivity, lower self-directedness, and lower cooperativeness 
(243,244). 
 
2.4.2. Etiology 
Both genetic and environmental factors are believed to be involved in the etiology of 
BN. Historically, eating disorders have been conceptualized as having sociocultural 
origins (idealization of slimness in the western world). Family history of eating 
disorders, depression, substance misuse (especially alcoholism) and obesity have been 
implicated as risk-factors, as well as premorbid experiences such as sexual abuse, 
family dieting, critical comments about eating, weight and body shape, and adverse 
parenting. Further implicated risk factors include premorbid personality characteristics 
such as low self-esteem, anxiety and anxiety disorders, and physical characteristics 
such as obesity and early menarche. Psychological theories include the need to feel in 
control of life as well as overvaluation of shape and weight (13).   
 
Eating disorders often run in families, and there seems to be cross-transmission 
between different eating disorders, suggesting a shared familial liability (245). Twin 
studies have enabled more detailed analyses on the contribution of heritability (the 
cumulative effect of different genes), shared environmental factors (environmental 
influences to which both members of a twin pair are exposed) and unique 
environmental factors (environmental factors to which only one member of a twin pair 
is exposed) (246). The heritability estimates for BN range between 28-83% (13,247-
250). The contribution of unique environmental factors is estimated to range between 
17 % (248) to 38 % (249).  
 
To date, only one linkage study for BN has been published, reporting significant 
linkage on chromosome arm 10p for a broad sample of families affected by BN (251). 
Association studies have explored the impact of several genes on BN, especially the 
genes affecting the 5-HT system. Most investigated is the association of BN and 5-
HTTLPR polymorphism. Although one study found an association between the 5-
HTTLPR genotype and BN (252), other studies have not replicated the finding 
(253,254). However, some studies have found an association between the 5-HTTLPR 
genotype and particular predisposing eating disorder-related behavioral and attitudinal 
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traits (254-256). Same applies for polymorphism of genes coding for 5-HT2A receptor 
(257), 5-HT2C-receptor (256), catecholamine-O-methyltransferase (COMT) (255), and 
tryptophan-hydroxylase-1 (258). Other investigated genes include e.g., genes coding for 
leptin (no association) (259), brain derived neurotrophic factor (BDNF) (discrepant 
findings) (260-262), and ghrelin (discrepant findings) (263,264).  
 
2.4.3. 5-HT function in Bulimia Nervosa 
Neurobiological alterations are found in subjects affected by BN, which has lead to the 
question whether these alterations are a cause or consequence of the disorder. Most 
evidence exists on the role of 5-HT. The monoamine system has been the most obvious 
target for investigations as the medications acting on monoamine neurotransmitters are 
used in treatment of psychiatric disorders. However, it is possible that other systems 
have a role, too, and furthermore, that the alterations detected in the 5-HT system are 
not primary but instead reflect alterations in some other aspects of neurobiology. 
 
Several study results have lead to the 5-HT hypothesis in BN:  
 
1. 5-HT has effect on food intake and body weight (11), which may contribute to 
appetite dysregulation in eating disorders. 
2. BN is often accompanied by disturbances of mood and impulse control (240), in 
which disturbed 5-HT function has also been implicated (5,15). 
3. Subjects who are ill with BN show several abnormalities in 5-HT metabolism and 
function as compared to healthy subjects. The neuroendocrine responses to 
intravenous 5-hydroxytryptophan and d,l-fenfluramine hydrochloride are blunted 
(265,266); the CSF levels of 5-HIAA are reduced in a subgroup of more frequently 
binge-eating in bulimic subjects (267,268); and the mood lowering effect of acute 
TRP depletion is increased (269) in BN. Three PET or SPET studies have 
previously investigated subjects ill with BN, reporting reduced SERT binding in 
the hypothalamus/thalamus (181), increased 5-HT1A binding in the frontal, 
cingulate, temporal, and raphe regions (270), and normal 5-HT2A receptor binding 
(271).  
4. The SSRI medications, especially fluoxetine, are at the moment the most effective 
treatment for BN, despite the fact that not all affected subjects benefit from it (16). 
 
It is not known whether the disturbances in 5-HT system in BN and in other eating 
disorders are a cause (i.e., genetic trait making a subject vulnerable for getting the 
disease) or a consequence of the dysregulated eating behavior (i.e., a state resulting 
from changes in nutritional status during the illness). The heritability of eating disorders 
(247-250) as well as the existence of particular premorbid temperament characteristics 
that persist after recovery suggest that there may be a trait for developing an eating 
disorder (6). The premorbid temperament characteristics include childhood 
perfectionism, obsessive-compulsive personality patterns, and anxiety (272-274). After 
recovery from BN, persistence of mild to moderate negative moods and obsessions with 
perfectionism and exactness has been reported (275). A neurobiological disturbance 
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may underlie the vulnerability for BN and remain after recovery. Studying individuals 
before the onset of illness is obviously difficult. Studying individuals after recovery is 
easier and has been done in BN subjects. These studies show some persistent alterations 
in the 5-HT system that may represent a trait and predispose a subject for BN. In 
recovered BN subjects, acute tryptophan depletion caused lowering of mood, increases 
in ratings of body image concern, and subjective loss of control of eating (276). PET 
studies have shown loss of normal age-related decline in the 5-HT2A binding in subjects 
who have recovered from BN (277).  
 
The problem of interpreting studies in recovered subjects lies in the fact that it is not 
possible to differentiate whether the detected finding is due to a trait or represents 
scarring caused by the state. Twin studies with discordant monozygotic twin pairs offer 
one possibility for overcoming this problem, as a trait effect should be found also in the 
genetically similar co-twin.  
 
2.4.4. Treatment 
According to a recent review, several studies have shown that fluoxetine (60 mg/day) 
reduces core bulimic symptoms (binge eating and purging) and associated 
psychological features in the short term. Single studies provide preliminary evidence on 
the beneficial effect of fluvoxamine, trazodone, desipramine, topiramate, ondansetron 
and brofaromine (16). Cognitive behavioral therapy (CBT) decreases core behavioral 
symptoms and psychological features in both the short and long term (16), and, 
according to another review, may be the most effective treatment for BN (278). How 
best to treat individuals who do not respond to CBT or fluoxetine remains unknown 
(16). 
 
2.5. OBESITY 
2.5.1. Overview 
Overweight and obesity are defined as abnormal or excessive fat accumulation that 
presents a risk to health. The most commonly used population measure of obesity is the 
body mass index (BMI), a person’s weight (in kilograms) divided by his or her height 
squared (in metres). A person with a BMI of 30 or more is generally considered obese. 
A person with a BMI equal to or more than 25 is considered overweight (17). 
 
Obesity is one of the main health issues of our time, and has spread so rapidly in 
recent decades that it has become popular to talk about it as “the obesity epidemic”. In 
the year 2005, the prevalence of obesity in Finland was 17.8 % for women and 18.9 % 
for men, in the United Kingdom 24.2 % and 21.6 % respectively, and in the United 
States 41.8 % and 36.5 % (279). It affects individuals of all ages: the World Health 
Organization (WHO) estimated that globally in the year 2005 approximately 1.6 billion 
adults (age 15+) were overweight, at least 400 million were obese, and at least 20 
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million children under the age of 5 years were overweight. Furthermore, by the year 
2015, approximately 2.3 billion adults are estimated to be overweight and more than 
700 million obese (17). The rapid spread of obesity is often associated to the western 
sedentary lifestyle, with excessive food supplies and lack of exercise. However, it is not 
only a problem of the westernized world; despite problems of malnutrition and 
starvation, obesity is increasing rapidly also in the developing world (280). Overweight 
and obesity are major risk factors for a number of chronic diseases, including diabetes, 
cardiovascular diseases and cancer (17). 
 
Overweight and obesity develop ultimately from an imbalance between ingested 
and expended energy, but the mechanisms of the underlying causative processes are 
still not fully understood. Alongside peripheral factors secreted by the pancreas, the gut 
and the adipose tissue, neuropeptides and neurotransmitters participate in the control of 
energy homeostasis (18). At the moment, more than 40 orexigenic and anorexigenic 
signalling molecules are known, including hormones, neuropeptides, neurotransmitters, 
enzymes, other chemical messengers and their receptors (19). Most of these factors 
exert their influence in the hypothalamus. Alongside the many signalling molecules, 
feeding behavior is affected by the brain reward circuitry involving the drive to obtain a 
rewarding stimulus as well as the hedonic experience of getting the stimulus (281).  
 
Although many factors underlie the causes of obesity, genetics is considered to play 
a significant role in regulation of energy balance and in the development of obesity 
(282). The influence of genetic factors is supported by several family and twin studies 
(283,284). The latest Human obesity gene map (year 2005) reported a total of 127 
candidate genes in association with obesity-related phenotypes. At least 22 of these 
genes are each supported by at least five positive studies (285). 
 
2.5.2. 5-HT and feeding behavior 
Serotonin is believed to be one of the many signalling molecules affecting feeding 
behavior, having an anorexigenic effect (11). This is suggested by several lines of 
evidence: In laboratory animals, artificial reductions in the brain 5-HT levels lead to 
hyperphagia and weight gain (286), whereas increases in 5-HT levels lead to 
hypophagia (287-289). Medications that increase brain 5-HT levels reduce feeding 
behavior and body weight (290,291). Elevated levels of 5-HT have been implicated in 
cancer anorexia (292). Studies also show that hypo-caloric diet reduces brain 5-HT 
levels in animals (293). In healthy humans, dieting causes reduction in plasma 
tryptophan levels (and thus likely also brain 5-HT levels) (294,295) and increases the 
sensitivity of postsynaptic 5-HT2C receptors (294). Reduced baseline 5-HT levels are 
reported in obese rats (296). In obese humans, plasma concentrations of tryptophan are 
reported to be low and do not normalize after weight reduction (297,298), suggesting 
persistent alterations in the serotonergic system. Taken together, the data suggest that 
reduced 5-HT transmission (caused by reduced extracellular 5-HT) is associated with 
increased appetite and obesity, whereas increased 5-HT transmission (caused by 
increased extracellular 5-HT) has a suppressive effect on feeding behavior and appetite.  
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Of the 5-HT receptors, the association of 5-HT2C and 5-HT1B receptors with feeding 
behaviour is the strongest. 5-HT2C receptor-deficient mice exhibit abnormal control of 
feeding behavior, leading to development of overweight (299). Also 5-HT1B receptor-
deficient mice exhibit increased body weight (300) and attenuated responses to classic 
anorectic 5-HT compounds like d-fen (301). Both 5-HT2C and 5-HT1B receptors affect 
feeding behavior by modulating the hypothalamic melanocortin system, leading to 
downstream activation of the melanocortin 4 receptor. Stimulation of the 5-HT2C 
receptors directly activates pro-opiomelanocortin (POMC) neurons in the arcuate 
nucleus of the hypothalamus, promoting the release of α-melanocyte stimulating 
hormone (α-MSH) (an anorexigenic factor) acting on melanocortin 4 receptor 
(302,303). Stimulation of 5-HT1B receptors first inhibits the release of Agouti Related 
Protein (AgRP), which leads to decreased inhibitory synaptic input onto POMC 
neurons, and thus also promotes the release of α-MSH (304). Other 5-HT receptors, 
e.g., 5-HT1A, 5-HT2B and especially 5-HT6 receptors have also been implicated as 
having association with feeding behavior (305).  
 
Some studies have also found associations between obesity and genes related to 5-
HT function. Three studies have found an association between the 5-HTTLPR genotype 
and obesity, reporting a higher frequency of obesity and higher mean BMI in carriers of 
the S allele: one study in Argentinean adolescents, showing association in both sexes 
(306); one study in Argentinean young adult men (307); and one longitudinal study in 
US citizens as adolescents and young adults, showing association in white and Hispanic 
men, but not in women or African American men (308). The last study also found 
higher BMI rise in carriers of the S allele when assessing change in BMI between two 
contacts (at about 16.5 and 22 years of age) (308). Genetic associations relating to the 
5-HT system have also been reported with polymorphisms of the SLC6A14 gene 
(309,310), MAO-A gene (308,311), 5-HT2A receptor gene (312,313) and 5-HT2C 
receptor gene (314,315). 
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3. STUDY OBJECTIVES 
 
 
1. To compare the repeatability of manual versus automated VOI placement in 
SERT binding quantification of [123I]ADAM images. 
 
2. To investigate the existence of seasonal variation in SERT binding 
 
3. To investigate the SERT binding of subjects with and genetically predisposed to 
Bulimia Nervosa 
 
4. To investigate the relationship between SERT binding and acquired obesity (as 
represented by body mass index) 
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4. METHODS 
4.1. STUDY DESIGN 
 
In study I, a brain template for the automated registration and realignment of 
[123I]ADAM-images was created from [123I]ADAM-scans of healthy women. 
Furthermore, a predefined volume of interest (VOI) map was created for the 
quantification of SERT binding. The repeatability of the automated procedure in 
quantifying SERT binding was tested by comparing SERT binding measurements 
between the results of initial fitting procedure to a second fitting performed after 
misalignment of the images.  The repeatability of the automated procedure was tested 
in a group of women with Bulimia Nervosa. 
 
SERT binding was also quantified using manual delineation of the VOIs. Manual 
VOI delineations of the midbrain and cerebellum (the reference region) were tested for 
intra- and inter-observer repeatability. Intra-observer repeatability was tested between 
repeated VOI definitions performed six months apart by a blinded observer (a nuclear 
medicine physician). Inter-observer repeatability was tested between the results of the 
first analysis by the first observer and results of VOI definitions done by a second 
blinded observer (a hospital physicist). For testing the intra-observer variability, we 
used [123I]ADAM-scans of healthy subjects (co-twins of subjects with an eating 
disorder) and of the group of women with BN. Inter-observer repeatability of the 
manual VOI definitions was tested in the group of BN women.   
 
In study II, the existence of seasonal variation in SERT binding was investigated by 
comparing the intra-subject variability of [123I]ADAM binding in the midbrain and 
thalamus of healthy young adults between two repeated [123I]ADAM-scans, performed 
in summer and in winter. Based on earlier results (164), we hypothesized higher SERT 
binding in summer as compared to winter. 
 
In study III, we investigated SERT binding in women with lifetime BN and in 
healthy women genetically predisposed to BN (twin-sisters of bulimic women) by 
comparing them to healthy women with no predisposition for BN. For this purpose, we 
used a twin sample (including both mono- and dizygotic twin pairs). SERT binding in 
the midbrain and thalamus was investigated both in individuals (clustering caused by 
inclusion of twins was taken into account for) and in twin pairs (within-pair 
comparisons), using [123I]ADAM as a SERT ligand. In post hoc analyses, a subgroup of 
purging BN women was compared with the healthy women. Based on earlier results 
(181), we hypothesized reduced SERT binding in the BN probands. Furthermore, we 
assumed that SERT transmission is a bulimia-related endophenotype, i.e., a heritable 
quantitative trait that is state-independent (manifest in the individual whether or not 
illness is active), and found more often in unaffected family members than in the 
general population. Therefore, we hypothesized that SERT availability would be clearly 
reduced in SERT rich brain regions in BN women compared to unaffected women, and 
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that the SERT availability of unaffected co-twins would be intermediate between that 
of probands and healthy women. 
 
In study IV, we investigated the relationship between acquired obesity and SERT 
binding in a sample of monozygotic (MZ) twins. BMI was used as an index of obesity. 
SERT binding was measured in the midbrain and hypothalamus/thalamus areas using 
[123I]nor-β-CIT as a ligand. The relationship between obesity and SERT binding was 
assessed both in individual data (clustering caused by inclusion of twins was taken into 
account for) and in twin pairs (within-pair comparisons, twin with higher BMI 
compared with co-twin with lower BMI). In post hoc analyses, the effects of sex and 
oral contraceptives on the SERT binding were investigated. 
 
In studies III and IV, we investigated twins and applied twin study designs in their 
simplest form, by:  
1) Comparing variables between probands, their unaffected co-twins and unrelated 
healthy subjects (study III) 
2) Comparing some variables between genetically similar (MZ) twins (within-pair 
analyses) (study IV), when the effect of genetic factors is eliminated and the observed 
differences will be caused by unique environmental influences.  
 
Twin studies investigating discordant twin pairs (one twin affected and the co-twin 
unaffected) and healthy control twin pairs offer an opportunity to explore the 
differences between genetic and environmental influences, given that the twins share 
either all or half their segregating genes with their affected co-twin, depending on 
whether the twin pair is monozygotic (MZ) or dizygotic (DZ). Moreover, twins are of 
the same age and have generally similar childhood and adolescent experiences. 
Observed differences between the affected twin and unaffected co-twin are likely due 
to state effects (caused by unique environmental effects), whereas differences observed 
between healthy twin sisters and unrelated controls would be trait-related (representing 
the effect of genes). Observed similarity of discordant twins would be explained by 
shared genetic liability as well as by shared environmental effects.  Studies published in 
the last few years have shown that epigenetic transformations play an important role in 
the discordance of MZ twins (316).    
 
4.2. STUDY SUBJECTS 
 
The study subjects of studies I-IV were recruited in three separate procedures, two of 
which involved screening subjects from the Finnish twin study FinnTwin16, a 
longitudinal national twin cohort including virtually all Finnish twins born in 1975-
1979 (317). The third subset of subjects were healthy young men recruited through and 
advertisement directed at male students.  
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4.2.1. Studies I-III 
4.2.1.1. Recruitment of study subjects  
In the studies I-III, we used [123I]ADAM-scans done for subjects screened from the 
FinnTwin16 twin cohort. In addition, healthy male, non-twin subjects were recruited 
specifically for the study II.  
 
Recruitment of twins for studies I-III: 2545 female twins were sent a self-report 
questionnaire screening for potential eating disorders at the age of 22-27 years. 292 
screen-positive women, their 130 female co-twins, and 210 screen-negative women 
were then interviewed using a short version of the Structured Clinical Interview for 
DSM-IV (SCID) (318) (interview participation rate 85.2 %) (319). From the interviews, 
we obtained lifetime diagnoses of AN, BN, BED, MDD and OCD. After exclusion of 
twin pairs who were not eligible for the study (due to pregnancy, having psychiatric 
morbidity other than BN, or medications affecting the 5-HT system) we ended up with 
15 twin pairs in which either one or both twins had DSM-IV criteria fulfilling lifetime 
BN, more broadly defined BN or other eating disorder. In 10 pairs one or both subjects 
had a DSM-IV criteria fulfilling lifetime BN; three pairs were concordant for BN and 
seven pairs were discordant for BN (one female-male pair). Five pairs (including two 
female-male pairs) were discordant for eating disorder symptoms not fulfilling the 
diagnostic criteria for BN; their brain scans were used only in study I. In addition, 10 
healthy pairs from the screen-negative twins took part in the studies. All 25 twin pairs 
went through SPET imaging with [123I]ADAM. Two healthy individuals from different 
healthy pairs were excluded from the analyses; one due to an earlier history of MDD 
and the other due to an unsuccessful radioligand injection. The scans performed to the 
remaining 48 subjects were used in studies I-III in different combinations. 
Furthermore, five women from 5 healthy twin pairs were scanned twice for the 
purposes of the study II on seasonal variation in SERT binding.  
 
Recruitment of healthy male subjects for study II:  For the study II on seasonal 
variation in SERT binding, we wanted to include healthy individuals from both sexes. 
As all the healthy twin pairs mentioned above were female-female pairs, we sought 
healthy young men to take part in the study through a separate recruitment process.  
This involved an advertisement of the study directed to healthy young adult male 
students. Nine men were initially investigated; one was excluded due to technical 
problems in the first scanning. Eight men were invited for a second scan a few months 
later; one of them declined the invitation, resulting in altogether seven healthy male 
subjects in study II.  
 
4.2.1.2. Study subjects in each study I-III  
In study I, all study subjects came from the twin sample. [123I]ADAM scans of 15 
healthy females were used for the formation of [123I]ADAM brain template. For the 
repeatability analyses of the automated system, scans of 10 BN women were used. For 
intra-observer repeatability analyses of manual VOI definitions we used brain scans of 
(i) 11 healthy co-twins (including two males) of subjects affected by an eating disorder 
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and (ii) 10 women with BN. For inter-observer repeatability analyses of manual VOI 
definitions we used the brain scans of 10 women with BN 
 
In study II, we performed [123I]ADAM scans to 12 (five women and seven men) 
healthy subjects twice, in summer and in winter. Five of the subjects were healthy 
women from the twin sample (age in summer 26.8 ± 0.84 years and in winter 26.4 ± 
1.14 years; body mass index (BMI) in summer 21.54 ± 4.14 kg/m2 and in winter 21.84 
± 4.07 kg/m2). Their first [123I]ADAM scans had been performed in winter for the 
purposes of studies I and III, and they were then asked if they would be willing to be 
investigated for a second time, in summer. Only one healthy female per healthy twin 
pair was invited. Seven subjects were healthy males (age in summer 23.29 ± 1.60 years 
and in winter 23.57 ± 1.99 years; BMI in summer 23.99 ± 2.30 kg/m2 and in winter 
24.16 ± 2.58 kg/m2) enrolled for the study in a separate process as described above.  
None of the study subjects were alcoholics and four smoked cigarettes regularly. 
 
In study III, we investigated three groups of subjects:  
 
1) The BN women; 13 women fulfilling the DSM-IV criteria of lifetime BN (seven 
women from BN-discordant twin pairs (one MZ pair and six DZ pairs) and six women 
from three BN-concordant twin pairs (2 MZ and 1 DZ pairs). Their ages were 24.8 ± 
1.7 years and BMIs 22.9 ± 3.2 kg/m2. 
 
2) The unaffected female co-twins of the BN women; six healthy women (one from 
MZ and five from DZ twin pairs). Their ages were 24.8 ± 2.1 years and BMIs 23.6 ± 
3.2 kg/m2. 
 
3) The healthy women; 18 women from 10 twin pairs (5 MZ and 5 DZ female-female 
pairs). Their ages were 25.3 ± 1.7 years and BMIs 22.2 ± 3.5 kg/m2. 
 
Male co-twins were excluded from the study. 
 
4.2.2. Study IV 
The subjects for Study IV were also enrolled from the FinnTwin16 twin cohort. 658 
MZ twin pairs were screened at age of 23–27 years based on their responses to 
questions on weight and height. 16 healthy MZ twin pairs (eight female and eight male 
pairs, ages 24-27 (25.42 ± 1.29) years) were selected on the basis of their intrapair 
difference in BMI so that twin pairs with both similar and divergent BMIs were 
included. One of the male twins had very high BMI due to muscularity (BMI 31.46 
kg/m2 and fat percentage 11 %) and as we wanted to use BMI as an index of obesity, 
we excluded him from the analyses of individual data and the twin pair from the 
analyses of pairwise data. For the remaining 31 individuals, the BMIs ranged from 19.1 
to 31.9 kg/m2 (mean 25.57 ± 3.45 kg/m2) and the intrapair BMI differences ranged from 
0.31 to 8.1 kg/m2 (mean 2.24 ± 2.12 kg/m2). The mean intrapair weight difference was 
6.32 ± 6.25 kg. All subjects were healthy and none of the women were pregnant. None 
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of the subjects used concomitant medications except oral contraceptives (n = 6, in 3 
twin pairs). Two subjects were current smokers. None used alcohol daily, but seven 
subjects reported weekly use of alcohol. 
 
4.3. ASSESSMENT OF CLINICAL, PSYCHIATRIC AND 
BEHAVIOURAL CHARACTERISTICS 
 
In studies I-III, the subjects’ somatic health was classified as normal based on 
interviews performed by MDs (AK, AK-R, ES). For subjects in study IV, a more 
detailed assessment of somatic health was made, including laboratory tests as well as 
clinical examination by an MD (KP). In each subject, body weight and height were 
measured, and the BMI was calculated as body weight (in kilograms) divided by height 
(in meters) squared. In study IV, body composition was measured by bioelectrical 
impedance analyser (STA/BIA with Bodygram software; Akern, Florence, Italy). 
 
For the twin subjects in studies I and III, a detailed psychiatric and behavioural 
assessment was done. Initial screening was done by sending 2545 female twins a 
questionnaire including questions on current height and weight, ideal weight, minimum 
and maximum weight at current height, purging, and weight loss behaviors, as well as 
assessment of body image by use of three subscales (body dissatisfaction, drive for 
thinness, and bulimia) of the Eating Disorder Inventory (320). Secondly, the screen-
positive women were telephone-interviewed with short version of SCID-I interview 
(318) for obtaining the lifetime diagnoses of AN, BN, BED, MDD and OCD. Thirdly, 
face-to-face interviews with EATATE (274) and Semi-Structured Assessment for the 
Genetics of Alcoholism (SSAGA) (321,322) were done for the BN women and for their 
healthy co-twins and the healthy control twin pairs. The EATATE is a semi-structured 
clinical interview based upon the Eating Disorders Examination (323) but adapted to 
assess lifetime symptoms of ED following the Longitudinal Interval Follow-up 
Evaluation (324). SSAGA is a fully structured, poly-diagnostic psychiatric interview 
that is used to make substance use disorder and psychiatric disorder diagnoses 
according to DSM-III-R criteria (325) 
 
For those healthy females participating also in study II, psychiatric interviews were 
performed once, before the first [123I]ADAM scan. For the male subjects in study II, no 
structured psychiatric interviews were performed. Their classification as mentally 
healthy was based on self-report.  
 
For subjects in study IV, structured psychiatric interviews (SSAGA) (321) were 
performed to exclude lifetime psychiatric diagnoses. 
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4.4. ASSESSMENT OF ZYGOSITY 
 
The zygosity of all twin pairs was confirmed by genetic blood marker tests using the 
highly polymorphic, multiple genetic marker set used in the Paternity testing 
laboratory, National Public Health Institute, Helsinki, Finland. 
 
4.5. SERT IMAGING 
4.5.1. Radioligands  
4.5.1.1. [123I]ADAM  
Iodine 123-labeled 2-((2-((dimethylamino)methyl)phenyl)thio)-5-iodophenylamine 
([123I]ADAM) (MAP Medical Technologies Oy, Tikkakoski, Finland) was used to 
assess SERT binding in studies I-III. Thirty minutes before its intravenous injection, 
the subjects were given 400 mg of potassium perchlorate orally to reduce [123I]-uptake 
in the thyroid and the salivary glands. Injected radioactivity of [123I]ADAM varied 
between 139-231 MBq. All radioligand injections were given at 8 o’clock a.m. 
following an overnight fast.  
 
[123I]ADAM binds selectively to SERTs, with an affinity to SERTs more than 1000-
fold over its affinity to dopamine transporters (DATs) and norepinephrine transporters 
(NETs) (216). Its binding is greatest and least variable in a test-retest setting in the 
midbrain and thalamus and reaches pseudoequilibrium at 4-6 h post injection (217). Its 
effective dose is similar to the other commonly used radioligands (220,221).  
 
4.5.1.2. [123I]nor-β-CIT  
Iodine 123-labeled 2β-carbomethoxy-3β-(4-iodophenyl) ([123I]nor-β-CIT), supplied by 
MAP Medical Oy, Tikkakoski, Finland, was used for investigating SERT binding in 
study IV. The mean injected dose of 196.3 MBq (range 187-206 MBq) was given to 
subjects as an intra venous injection, following an overnight fast. Potassium perchlorate 
was given to subjects before the radioligand injection for reduction of [123I]-uptake in 
the thyroid and the salivary glands.  
 
[123I]nor-β-CIT is an analogue of [123I]β-CIT with a high affinity to both SERTs and 
DATs. It has a tenfold higher affinity to SERTs in comparison to [123I]β-CIT (213). In 
the midbrain and hypothalamus/thalamus its binding is considered specific, but not 
selective, to SERTs. In a autoradiography displacement study in post-mortem human 
brains, the SERT blocker citalopram fully inhibited [123I]nor-β-CIT:s binding to the 5-
HT rich thalamus (214), suggesting that [123I]nor-β-CIT:s binding in the 
hypothalamus/thalamus is specific to SERTs. In a study in living humans, 
administration of the SERT blocker citalopram to one of the study subjects reduced 
[123I]nor-β-CIT:s binding in the midbrain by 52% (215), supporting the view that 
[123I]nor-β-CIT binds to SERTs also in the midbrain. The reported effective dose 
equivalent of [123I]nor-β-CIT is 0.035 mSv/MBq (215).  
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4.5.2. SPET procedures 
4.5.2.1. SPET studies using [123I]ADAM 
Data acquisition and reconstruction into images:  
The SPET scans in studies I-III took place in the Nuclear Medicine Laboratory of the 
Helsinki University Central Hospital. The acquisitions were carried out 10 minutes and 
5 hours after the radioligand injection. We used a Philips Picker Prism3000XP three-
headed gamma camera with ultra-high-resolution fan-beam collimators (Philips 
Medical Systems, Cleveland, OH, USA). The fan-beam focus of the collimator was 535 
mm and the radius of rotation, measured from the surface of the collimator, varied 
within 130-160 mm, depending on the patient. The acquisitions were performed using a 
120° orbit in a stepwise mode. The subject’s head was positioned to the centre of 
rotation in the head locker using a crossed laser beam system for repositioning. For 
repeated scans, the same positioning information (position and height of the bed) were 
used. A symmetrical energy window for 123I was used (159 keV; 20 % wide, 143 keV – 
175 keV). We used a 128 x 128 matrix size with 120 projection angles (40 
projections/detector). The data were collected for 45 s per projection angle, resulting in 
an average of 50 kilocounts (kcts) per projection in the acquisitions at 10 min and about 
20 kcts at 5h.  
 
All reconstructions and image analyses were done on HERMES software system 
(Hermes Medical Solutions, Stockholm, Sweden), using iterative reconstruction 
program HOSEM (OS-EM V5.201 by R. Larkin). The decay-corrected reconstructed 
transverse slices were oriented to the orbitomeatal line. The number of subsets was 8 
with 6 iterations. Attenuation correction was performed during the reconstruction using 
Chang’s first-order approximation with the linear attenuation correction (µ = 0.110 cm-
1), which was based on an ellipse contour of the brain. The images were post-filtered 
using a Butterworth filter with cut-off frequency of 1.2 cm-1 and order 15. 
 
Creation of [123I]ADAM template and the predefined VOI map: 
A brain template for [123I]ADAM-images was created in study I and later used for 
automated registration and formation of stereotactic [123I]ADAM images from 
individual [123I]ADAM scans in studies I-III. For the formation of the template, we 
used [123I]ADAM-scans performed for 15 healthy women. The subjects had earlier 
been investigated by magnetic resonance imaging (MRI) (Siemens Vision 1.5T with 
MP_RAGE sequence; Siemens AG, Erlangen, Germany). An MRI scan of one 
arbitrarily chosen study subject was chosen as a starting point to which her [123I]ADAM 
scan was then co-registered. Registration was performed with the application 
MultiModality on HERMES using an automatic algorithm with 6 degrees of freedom 
(size changes were restricted) and “Mutual Information” method as measure of 
similarity. The [123I]ADAM-scans of the remaining 14 subjects were then spatially co-
registered with the first one using BRASS (Brain Registration and Analysis of SPECT 
Studies) software (Hermes Medical Solutions, Stockholm, Sweden) on a HERMES, 
using 9 degrees of freedom and Mutual Information. The 15 co-registered SPET scans 
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were normalized to total counts and averaged to build a template containing mean 
values and distributions in every pixel. Anatomically standardized normal reference 
template was created using the Modelgen software (Hermes Medical Solutions, 
Stockholm, Sweden).   
 
The template was then used in conjunction with the – intrinsically co-registered – 
sample MRI to define a set of volumes of interests (VOIs) for all further analyses. 
Initially a VOI map with several regions was generated, but due to [123I]ADAM’s 
reproducibility issues (217), we only used the midbrain and thalamus VOIs as our 
target regions and the cerebellum VOI as a reference region (326) in studies II and III. 
The automated VOI quantification was performed using the anatomically standardized 
(stereotactic) images. In studies II and III, we chose to adjust the location of the 
midbrain VOI slightly manually, if its automated positioning did no seem exact in 
visual inspection. The possible moving of the midbrain VOI was then done without 
altering its size or the transverse slice, to which it was placed by the automated 
procedure.  
 
Repeatability analyses: 
In study I, the misalignment of the [123I]ADAM scans following the initial 
automated registration of the scans to the template was performed using randomly 
selected values generated in Excel2000 (Microsoft Corporation, USA).  Misalignment 
parameters varied between 10 pixels in translation in X, Y and Z directions, 10 % in 
scaling and 10° in rotation. Because YZ rotation might vary more depending on patient 
positioning, this parameter was defined to vary up to 20°. 
 
In study I, we also tested the intra- and inter-subject variability in manual VOI 
drawing. For this purpose, [123I]ADAM images were first reconstructed, attenuation 
corrected and reoriented to the orbitomeatal line. Every two consecutive transaxial 
slices were then summed together, and the VOIs were drawn onto these summed slices.  
The midbrain VOIs were drawn onto images obtained from the acquisitions at 5 hours. 
The cerebellum VOIs were initially drawn onto the brain perfusion phase images 
obtained at 10 minutes, after which the VOI was transferred to the 5 hour images for 
quantification of SERT binding. The lower threshold of 30% was used in all VOI 
definitions.  
 
Estimation of SERT binding: 
In studies I-III using [123I]ADAM,  SERT binding was estimated by using the 
simple ratio method applying the formula Specific Binding Ratio (SBR) = (mean 
counts in the target area - mean counts in cerebellum) / mean counts in cerebellum.  
 
4.5.2.2. SPET studies using [123I]nor-β-CIT  
Data acquisition and reconstruction into images:  
The SPET scans in the study IV, applying [123I]nor-β-CIT as a SERT ligand, were 
performed at the Department of Clinical Physiology and Nuclear Medicine of the 
Kuopio University Hospital. The acquisitions were performed at 5 minutes, 6 hours and 
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24 hours after the injection of the ligand by a dedicated Siemens MultiSPECT 3 gamma 
camera with fan-beam collimators (Siemens Medical Systems; Hoffman Estates I11., 
USA). Head positioning was monitored by using two position lasers. The SPET scans 
were decay-corrected and reconstructed with Butterworth-filtered back-projection in a 
128×128 matrix with a pixel size of 3×3 mm, and attenuation-corrected with Chang's 
algorithm. The attenuation correction was uniform with the attenuation coefficient of 
0.11 cm-1. The SPET slices were consecutively summarized to the slice thickness of 6 
mm and re-aligned using a Siemens semi-automatic brain quantification program and 
the Talairach coordinates (327). The slices were rotated and re-aligned so that 
transaxial (x-direction), sagittal (y-direction) and coronal (z-direction) slices were at 
right angles to each other.  
 
VOI placement was done using a semi-automatic brain quantification program of 
Siemens. The lower threshold of 60 % of the maximum count was used to reduce the 
volume averaging and partial volume errors. Target VOIs (included in the present 
work) were the midbrain and hypothalamus/thalamus, and the cerebellum VOI was 
used as a reference region (326).  
 
Estimation of SERT binding 
In study IV using [123I]nor-β-CIT, we applied a graphical reference tissue method 
(328,329) to estimate the specific binding in terms of distribution volume ratios 
(DVRs). For calculating DVR, the integrated tissue radioactivity from time zero to T, 
normalized to tissue activity at time T, was plotted versus the integrated cerebellar 
time-activity data, which were also normalized to tissue activity at time T. This plot 
becomes linear when pseudoequilibrium is reached and the slopes for the midbrain and 
hypothalamus/thalamus data equal DVR. DVR is related to binding potential through 
formula BP = DVR - 1 (329).  The model is based on the assumption that flux from the 
free tissue compartment to arterial plasma compartment remains constant in the target 
and reference regions.  
 
4.5. STATISTICAL ANALYSES 
 
In studies II-IV, the data were analyzed using the Stata software (release 8.2; Stata 
Corp., College Station, TX, USA). All data were normally distributed. 
 
In study I, the inter- and intra-observer repeatability of the SERT binding 
quantification based on manual VOI definition and the repeatability of the SERT 
binding quantification based on automated method were investigated (i) graphically by 
using a Bland-Altman plot, where the difference between measurements is plotted 
against their mean value; and (ii) by calculation of coefficient of repeatability values 
(s), determined as twice the standard deviation of differences between analyses 
(330,331). The difference between the automated registrations for each patient was also 
evaluated comparing the initial registration to the second registration (following 
misalignment of the images) on a voxel-by-voxel basis, and calculating the mean 
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variation of the two registered studies, which describes the percentage difference or 
change in voxels between the two registrations.   
 
In study II, the paired nonparametric Wilcoxon tests were used for within-subject 
comparisons of the summer and winter data, and the multiple linear regression analyses 
were used to test the effects of multiple explanatory variables on a response variable. 
 
In studies applying twin design (studies III and IV), the analyses were done both 
for individual and for pair-wise data. In individual data, the bias caused by inclusion of 
genetically similar subjects was taken into account for by adjusting for clustering of 
twins within pairs using estimation procedures for complex survey methods. In Stata, 
the procedures SVYMEAN, SVYTEST (Wald test) and SVYREG (multiple linear 
regression analysis) permit derivation of the proper standard errors, variances, 
confidence intervals and P values, correcting for dependency within a twin pair. For 
comparison of more than two groups, we used one-way analysis of variance, and then 
appropriate two-group tests. 
 
For within-pair comparisons of the variables, we used the paired nonparametric 
Wilcoxon tests. In study III, Wilcoxon tests were used to compare the BN women with 
their healthy co-twins and in study IV, they were used to compare the twin with higher 
BMI to his/her leaner co-twin. In studies III-IV, we also calculated the mean intrapair 
differences between the twin and the co-twin for various variables and then computed 
Spearman correlations between the difference variables; for this analysis the unit of 
observation is the twin pair and all observations are statistically independent of each 
other. 
 
Data are shown as mean ± standard deviation, except for multiple regression 
analyses, where β-coefficients ± standard errors are shown. P values less than 0.05 were 
considered statistically significant. 
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5. RESULTS 
 
5.1. COMPARISON OF REPRODUCIBILITY OF MANUAL AND 
AUTOMATED QUANTIFICATION TECHNIQUES FOR SERT 
BINDING IN STUDIES WITH [123I]ADAM 
 
For the automated method, the Bland-Altman plot of the midbrain SBRs yielded from 
two automated registrations and VOI placements can be seen in Figure 3. The 
coefficient of repeatability for the specific binding ratio (SBR) in the midbrain VOI was 
s=0.13.  The mean variation between the first and second automated fitting procedures 
(describing the percentage difference in all voxels between the two registrations) was 
0.38 ± 0.15%.  
 
 
 
Figure 3. Repeatability of the midbrain SBR by the automated method. 
 
For the SBRs yielded by manual VOI definition, the Bland-Altman plots for intra- 
and inter-observer repeatability are shown in Figure 4. The intra-observer coefficient 
of repeatability for analyses of the 10 BN subjects was s=0.70. For the same study 
subjects, the inter-observer coefficient of repeatability was s=1.00.  
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Figure 4. Intra- and inter-observer repeatability of the manual VOI drawing.
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5.2. Seasonal variation in SERT binding of [123I]ADAM 
 
Table 3. The specific binding ratios of [123I]ADAM at five hours after injection 
 Midbrains Midbrainw p-
value* 
Thalamuss Thalamusw p-
value* 
All subjects (n=12) 2.04 ± 0.30 2.04 ± 0.25 0.81 1.56 ± 0.33 1.52 ± 0.31 1.00 
Women (n=5) 2.04 ± 0.18 2.03 ± 0.14 0.89 1.68 ± 0.45 1.35 ± 0.17 0.22 
Men (n=7) 2.04 ± 0.38 2.04 ± 0.33 0.87 1.48 ± 0.22 1.64 ± 0.34 0.31 
s=summer, w= winter, * Wilcoxon signed-rank test 
 
Table 3 summarizes the main findings of SERT binding of [123I]ADAM at summer and 
winter. No systematic variation in SERT binding of [123I]ADAM was evident in either 
the midbrain or thalamus. This was true for both sexes. Figure 5 further illustrates the 
lack of systematic differences between summer and winter scans; in both investigated 
areas, half of the subjects had higher SERT binding in summer and the other half in 
winter. Non-specific binding of [123I]ADAM (as measured by the cerebellar activity) 
was also similar in summer (93.03±15.51 in counts/pixel/kBq) and winter (93.64±14.21 
counts/pixel/kBq) scans (p=0.92).  
 
 
Figure 5: The specific binding ratios (SBRs) of SERT binding of [123I]ADAM in summer and 
winter in the midbrain and thalamus. 
 
 
The subjects’ BMIs were similar at both scans (summer: 22.97 ± 3.27 kg/m2, 
winter: 23.19 ± 3.33, p=0.08). [123I]ADAM dose, BMI, and smoking had no significant 
effect on the SERT binding in either season. 
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5.3. SERT AVAILABILITY IN SUBJECTS AFFECTED BY OR 
GENETICALLY PREDISPOSED TO BULIMIA NERVOSA 
5.3.1. Demographic variables and behavioural assessments   
The BN women, their unaffected sisters and the healthy twin women had similar ages 
(24.8 ± 1.7 y, 24.8 ± 2.1 y, and 25.3 ± 1.7 y, p= 0.81) and BMIs (22.9 ± 3.2 kg/m2, 23.6 
± 3.2 kg/m2, and 22.2 ± 3.5 kg/m2, p= 0.68). In the group of 13 women with lifetime 
BN, 11 were currently symptomatic, while two had been asymptomatic for three and 
five years. The mean age of onset of BN was 18.3 years (SD: 2.9 y, range: 13 - 21 y) 
and its mean duration was 6.5y (SD: 4.4 y, range: 6 months - 14 y). Nine of the 13 BN 
women suffered from the purging subtype of BN, and four were diagnosed with the 
non-purging subtype. Compensatory behaviors other than vomiting included diuretics 
and Ipecac abuse, excessive exercise, and fasting. Five individuals had a past history of 
anorexic symptoms, but had been asymptomatic for more than 6 months prior to our 
study. One of the BN women had current MDD, and seven BN women had a history of 
MDD. None of the healthy sisters or healthy control women had past or present 
psychiatric morbidities.  
 
5.3.2. SERT binding in women with BN, their unaffected sisters and non-
related healthy twin women  
As shown in Table 4, the BN women, their unaffected sisters and the unrelated healthy 
control women had similar SBRs of [123I]ADAM to SERTs both in the midbrain and 
thalamus. The unaffected sisters and the other healthy controls did not differ in their 
SBRs in the midbrain (p= 0.68) or thalamus (p= 0.65), and therefore we combined 
these two groups of healthy women. When BN women were compared with all the 
healthy women combined, no significant differences were found either in the midbrain 
(BN: 2.23 ± 0.22, all healthy: 2.06 ± 0.30, p= 0.08) or thalamus (BN: 1.45 ± 0.23, all 
healthy: 1.42 ± 0.28, p= 0.45). Removal of the two currently unsymptomatic women 
from the group of probands did not affect these results (data not shown). SERT binding 
in the cerebellum (i.e., non-specific uptake) did not differ between the groups (98.99 ± 
17.53 counts/pixel/kBq for the subjects with lifetime BN, 93.38 ± 21.42 
counts/pixel/kBq for the healthy co-twins and 96.52 ± 15.26 counts/pixel/kBq for the 
healthy controls, p=0.73). 
 
Table 4. SBRs for women with lifetime BN, their healthy co-twins and healthy control women 
 BN women  (n=13) Twin-sisters (n=6) Controls (n=18) p-value* 
Midbrain 2.23 ± 0.22 2.02 ± 0.29 2.07 ± 0.31 0.21 
Thalamus 1.45 ± 0.23 1.38 ± 0.25 1.43 ± 0.29 0.86 
*Significant differences between the groups were calculated using ANOVA: p-values were corrected for 
clustered sampling caused by inclusion of twins.  
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In post hoc comparison of the subgroup of purging BN women and the healthy 
women, the BN probands had significantly increased SERT binding in the midbrain. 
No differences were evident in the thalamus (Table 5).  
 
Table 5. SBRs: Comparison of the subgroup of purging BN women and all the healthy women  
 Women with purging BN (n=9) All healthy women (n=24) p-value* 
Midbrain  2.26 ± 0.19 2.06 ± 0.30 0.03 
Thalamus 1.50 ± 0.25 1.42 ± 0.28 0.45 
* t-test; p-values were corrected for clustered sampling caused by inclusion of twins.  
 
5.3.3. The effect of past psychiatric comorbidities on individual data 
The effects of MDD and past history of AN on the results were also explored. When 
subjects were grouped on the basis of MDD history, the subjects with (n=7) and 
without (n=30) MDD history had similar SBRs both in the midbrain (SBRMDD 2.20 ± 
0.22, SBRno-MDD 2.10 ± 0.30, p=0.38) and thalamus (SBRMDD 1.48 ± .28, SBRno-MDD 
1.42 ± .26, p= 0.63). Regarding past AN, the mean SBRs for SERT binding were very 
similar for the BN women with (n=5) and without (n=8) past history of AN both in the 
midbrain (SBRAN 2.25 ± 0.26, SBRno-AN 2.21 ± 0.22) and thalamus (SBRAN 1.50 ± 0.28, 
SBRno-AN 1.42 ± 0.21). In multiple linear regression analysis, history of AN or MDD 
had no effect on the results, whereas the effect of purging remained significant (Table 
6). 
 
Table 6. Multiple regression analysis examining the relationship of SERT binding with purging BN 
and past histories of Major Depression and Anorexia Nervosa  
 
MIDBRAIN: R2 = 0.10, F(3,17) = 3.92, p = 0.03 β S.E. of β p-value* 
Purging BN  -0.22 0.09 0.02 
History of major depression 0.08 0.10 0.44 
History of AN -0.08 0.09 0.38 
    
THALAMUS: R2 = 0.03, F(3,17) = 1.02, p = 0.41 
 
β S.E. of β p-value* 
Purging BN -0.10 0.06 0.14 
History of major depression  0.02 0.09 0.80 
History of AN -0.04 0.12   0.72 
*p-values were corrected for clustered sampling caused by inclusion of twins.   
 
5.3.4. Within-pair comparisons of SERT binding 
In within-pair comparisons, there were no differences in SBRs between a twin and her 
co-twin in neither of the brain regions in either the group of BN-discordant pairs (n=6 
pairs) or the group of healthy twin pairs (n=8 pairs).  The mean intrapair differences for 
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SBRs (SBR of twin 1-SBR of twin 2 in a given VOI) were also similar for the BN-
discordant twin pairs and the healthy control twin pairs.  Due to small number of pairs 
(n= 2), within-pair comparisons were not done for the pairs discordant for purging 
lifetime BN.  
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5.4. RELATIONSHIP BETWEEN BODY MASS INDEX AND THE 
BRAIN SERT BINDING 
  
5.4.1. BMI and SERT binding in individuals  
In individual data (the bias caused by inclusion of MZ twins taken into account for), 
BMI, weight or fat percent did not correlate with SERT binding in either the 
hypothalamus/thalamus or midbrain.  
 
The effect of sex and oral contraceptives: 
In post hoc analyses, the effects of sex and oral contraceptives on SERT binding 
were analyzed. In individual data, men as compared to women had significantly higher 
SERT binding in the midbrain (DVRmen: 1.37 ± 0.14, DVRwomen: 1.26 ± 0.12, p= 0.04). 
No significant differences between the sexes were evident in the 
hypothalamus/thalamus (DVRmen: 1.24 ± 0.16, DVRwomen: 1.10 ± 0.21, p=0.09).  
 
The 6 women using oral contraceptives (OCs) as compared to the 10 women 
without OCs had lower SERT binding in the hypothalamus/thalamus (DVROC: 0.94 ± 
0.08, DVRwithout-OC: 1.20 ± 0.20, p= 0.01). No significant differences were detected in 
the midbrain (DVROC: 1.30 ± 0.14, DVRwithout-OC: 1.24 ± 0.10, p= 0.45). Exclusion of 
the women with oral contraceptives did not change the outcome of comparison of 
SERT binding between the sexes. Men still had higher SERT binding in the midbrain 
than the remaining ten women (DVRmen: 1.37 ± 0.14, DVRwomen: 1.24 ± 0.10, p= 0.01), 
while similar SERT binding persisted in the hypothalamus/thalamus (DVRmen: 1.24 ± 
0.16, DVRwomen: 1.20 ± 0.19, p=0.63). 
 
5.4.2. BMI and SERT binding in twin pairs 
The results of within-pair comparisons are shown in Table 7. When twins were 
analyzed as pairs, comparing the twin with higher BMI to the co-twin with lower BMI, 
the twins with higher BMI had significantly higher SERT binding in the 
hypothalamus/thalamus than their co-twins. When men and women were analysed 
separately, the heavier women differed significantly from their leaner co-twins (p= 
0.01), but no differences were found in men (p= 0.61). No significant within-pair 
differences in SERT binding were found in the midbrain.  
 
The calculated intrapair differences in SERT binding did not correlate significantly 
with intrapair differences in BMI, weight, or body fat percentage in either the midbrain 
or hypothalamus/thalamus.  
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Table 7. BMIs, weights, fat percentages and SERT binding in pair-wise data. 
 Twin with 
higher BMI 
Co-twin with 
lower  BMI 
*p-value  Intrapair 
difference 
 
All twin pairs (n=15 pairs) 
    
BMI (kg/m2) 26.76 ± 3.61 24.52 ± 3.08 0.0007 2.24 ± 2.12 
Weight (kg) 77.96 ± 12.74 71.64 ± 11.96 0.0012 6.32 ± 6.25 
Percent whole body fat  28.91 ± 8.41 26.34 ± 8.29 0.0125 2.57 ± 3.27 
SERT binding (DVR**):     
 Hypothalamus/thalamus  1.21 ± 0.23 1.12 ± 0.16 0.04 0.09 ± 0.18 
 Midbrain  1.34 ± 0.15 1.30 ± 0.14 0.29 0.04 ± 0.16 
 
    
Men (n= 7 pairs)     
BMI 26.46 ± 4.18 24.16 ± 3.50 0.02 2.30 ± 1.70 
Weight 84.19 ± 15.20 76.79 ± 12.98 0.02 7.41 ± 5.68 
Fat percent 22.77 ± 5.16 19.76 ± 4.13 0.09 3.01 ± 3.90 
SERT binding (DVR**):     
 Hypothalamus/thalamus  1.26 ± 0.22 1.22 ± 0.08 0.61 0.04 ± 0.23 
 Midbrain  1.41 ± 0.14 1.36 ± 0.14 0.24 0.05 ± 0.20 
 
    
Women (n= 8 pairs)      
BMI 27.02 ± 03.31 24.84 ± 2.86 0.01 2.18 ± 2.56 
Weight 72.51 ± 07.33 67.14 ± 9.59 0.03 5.38 ± 6.95 
Fat percent 34.26 ± 06.93 32.10 ± 6.45 0.05 2.18 ± 2.81 
SERT binding (DVR**):      
 Hypothalamus/thalamus  1.17 ± 0.24 1.04 ± 0.16 0.01 0.13 ± 0.13 
 Midbrain  1.28 ± 0.12 1.24 ± 0.12 1.00 0.03 ± 0.13 
*Wilcoxon signed-rank test; Data are shown as mean ± SD;  
**DVR= distribution volume ratio 
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6. DISCUSSION 
6.1. METHODOLOGICAL CONSIDERATIONS 
 6.1.1. Definition of volumes of interest  
VOI definition is one potential influencer of outcomes in imaging studies of the brain 
neurotransmitter systems, especially in small and macroscopically invisible nuclei such 
as the serotonergic raphe nuclei. Perhaps due to this lack of visualization in anatomical 
imaging methods such as MRI and computed tomography (CT), in many studies the 
VOIs of SERT rich areas have been drawn manually onto images on the basis of visual 
information of the SPET images. However, this method of VOI definition is liable to 
both intra- and inter-observer variability. Differences between observers caused by their 
“handwriting” are likely even in the setting of agreed count thresholds for VOI 
definitions, as shown in study I. Furthermore, even in case of one observer, handwriting 
can change especially if time passes between the occasions. In case of a highly 
experienced observer, the intra-observer variability is likely to be smaller, but may 
nevertheless have some impact on study results. In order to reduce the variability 
caused by VOI drawing, some studies have used VOIs of fixed size, e.g., spherical 
VOIs of a certain size (e.g., (181) ). In this way, the volume in which activity is 
measured is standardized, reducing one element of variability. If these VOIs are placed 
manually on the basis of visual information of the SPET data, some observer dependent 
variability is likely to remain.  
 
One way of standardizing VOI definition is to base it on boundaries of anatomical 
structures. This can be achieved by co-registration of individual MR images and 
SPET/PET images and by drawing the VOIs based on anatomical boundaries visible in 
MRIs. Unless some automated procedures for VOI definition are used, even this 
method has an element of subjectivity caused by manual definition of regions. 
Furthermore, small errors occurring in co-registration of MR and SPET images are 
possible. The MRI-based demarcation of some structures such as raphe nuclei is not 
possible due to their invisibility in MRIs.  
 
The disadvantage of VOI analyses is the need for prior determination of the 
volumes of interest, which may leave some significant effects undetected. Another 
disadvantage is the difficulty of inter-study comparisons (332).  
  
Radioligand specific brain templates are used increasingly for the automated 
registration and realignment of individual images (182-184). They can be used for 
formation of stereotactic images, which can thus be compared in a more standardized 
way, either with predefined VOIs or on a voxel-by-voxel basis. However, human brains 
differ in size and some individual variation may exist in the sizes of anatomical brain 
structures, which introduces a bias for binding estimation. In the fitting process the 
brain images are adjusted to fit the template, which may cause small alteration in the 
size of the structures, thus diluting or concentrating count densities. Voxel-based 
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methods, applying software such as the Statistical Parametric Mapping (SPM) 
(Wellcome Department of Imaging Neuroscience, UCL, London , UK) (185), offer the 
advantage of not limiting binding estimation to predefined regions. The downside of 
SPM is that the original images need to be smoothed in order to meet the requirements 
of the statistical assumptions and to compensate for the anatomical differences between 
subjects (332). 
 
When investigating small structures, partial volume effect (PVE) can affect the 
measured binding estimates. To a degree, it can affect all the above mentioned 
quantification techniques, but especially manual VOI drawing of small structures. The 
PVE is caused by two distinct phenomena (333). First is the image blurring caused by 
limited spatial resolution of the imaging system, causing spillover (and sometimes spill 
in) of activity between regions. This usually makes a small structure appear larger but 
dimmer. The significance of the spillover is greatest in small structures with high count 
densities, and leads to an underestimation of the true activity. The second phenomenon 
causing PVE is image sampling. This is caused by the fact that SPET and PET images 
consist of voxels, which do not match the actual contours of the tracer distribution. 
Most voxels therefore include different types of tissues, and the signal intensity in each 
voxel is the mean of the signal intensities of the underlying tissues included in that 
voxel. Although PVE influences especially binding estimates based on manual VOI 
delineation, it has some effect even in count densities of single voxels, and to a degree 
has effect on all methods. Some correction methods for PVE exist (333), but are not 
used routinely in SPET. No PVE corrections were performed in studies I-IV, which can 
have some effect on our results. 
 
In study I, we validated the automatic registration and realignment of [123I]ADAM-
images to a template and found it as a reproducible method. Use of the template-based 
registration and predefined VOI map produced reproducible SERT binding estimates, 
unlike manual VOI delineation. However, visual inspection revealed that VOI 
placement is sometimes not quite accurate, especially in the midbrain. In studies II and 
III, we thus decided to adjust the placement of the midbrain VOI manually, if 
considered necessary in inspection. In study IV, VOIs were drawn manually by highly 
experienced analyst. As discussed above, both these methods have their drawbacks. 
However, none of the methods described above are perfect and without the possibility 
of biasing factors. 
 
6.1.2. The radioligands  
Two SERT ligands were used in this thesis; [123I]ADAM and [123I]nor-β-CIT. Both 
have benefits over [123I]β-CIT, which until recently was the most popular SERT ligand 
in SPET studies. [123I]β-CIT has affinities for DATs, SERTs and to a minor degree to 
NETs (206-209), but its binding in the midbrain and hypothalamus/thalamus has been 
considered as specific for SERTs (208,210). However, considering that especially in 
the midbrain there are nuclei containing both DATs and NETs (211,212), the 
possibility remains that binding to DATs and NETs affects the results considered to 
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represent SERTs. The ligand used in study IV, [123I]nor-β-CIT, has also affinities for 
DATs and SERTs (213), but its affinity to SERTs is relatively higher than that of 
[123I]β-CITs, and it may thus be better suited for SERT imaging. [123I]ADAM on the 
other hand has over 1000-fold affinity for SERTs over other monoamine transporters 
(216), and its binding is thus considered as selective for SERTs. With its affinity 
profile, it competes with the SERT ligands used in PET studies, i.e. [11C]DASB, 
[11C]McN5652 and  [11C]MADAM (334). However, the better resolution of PET as 
compared to SPET favours the use of PET ligands in SERT imaging. [123I]ADAM has 
also some other properties that affect its suitability for SERT imaging. Its binding 
kinetics varies somewhat depending on the SERT density of the region (217,223), and 
theoretically, inter-individual differences in SERT densities can cause differences in its 
kinetics, too. In patients, these differences may be even greater and affect the SERT 
binding estimates between study populations.  
 
The test-retest variability of [123I]ADAM is not ideal, being 13% ± 11% in the 
midbrain, 16% ± 13% in the thalamus, and around 20% in the lower binding regions 
(217), and for this reason, we limited our SERT measurements to the midbrain and 
thalamus. Variability values expressed as percentages have not been published for 
SERT binding of [123I]nor-β-CIT, but its test-retest difference (mean absolute 
difference between test and retest) for the midbrain distribution volume ratios is 
reported to very low (VDtest: 1.27 ± 0.11, VDre-test: 1.27 ± 0.14, mean difference:  
0.00 ± 0.08)  (335). Of the other ligands for SERT imaging,  [11C]DASB and 
[11C]MADAM have slightly less variability in their binding, both having mean test-
retest difference less than 11 % in regions with high SERT densities (228-230). No test-
retest variability results have been published for SERT binding of [123I]β-CIT and 
[11C]McN5652. The intra-class correlation coefficients for [11C]DASB in the midbrain 
and thalamus areas are either of the same magnitude (228) as for [123I]ADAM (217) or 
better (229), while for [11C]MADAM, the reported ICCs in these two areas are worse 
than for [123I]ADAM (230). For [123I]nor-β-CIT, the ICC (in the midbrain) is slightly 
better than for [123I]ADAM (335). 
 
In some study subjects, lipophilic metabolites of [123I]ADAM have been reported, 
but as SERT blocker citalopram had no effect on their blood concentrations, they are 
unlikely to bind to SERTs (223). Also for [123I]nor-β-CIT at least one clearly lipophilic 
metabolite has been reported (215). However, no studies have been published on the 
effect of its metabolites on the specific binding estimates.   
 
Most studies (including ours) using [123I]ADAM as ligand have used the simple 
ratio method for the estimation of SERT binding. Initially, SERT binding quantification 
with a simple ratio method and by simplified reference tissue model (SRTM) (336) 
were compared to a full kinetic modelling with arterial blood sampling in baboons 
(337). Strong correlations between the full kinetic modelling and both non-invasive 
methods were detected. SRTM slightly underestimated and ratio method slightly 
overestimated SERT binding (337). Preliminary results (published as an abstract) in 
humans also showed a correlation between the SRTM and full kinetic modelling (338), 
supporting the use of non-invasive SERT quantification. Catafau et al (217) found good 
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correlations between the SRTM and ratio methods. However, the first paper comparing 
full kinetic modelling with several non-invasive quantification methods in humans was 
published only recently. That study reported only a moderate correlation between the 
ratio method and full kinetic modelling (r = 0.94) and considerable overestimation of 
specific uptake ratios (on average by 10% ± 28%). However, ratios were calculated 
from scans made at 200-240 min after injection, which may be a bit early considering 
the reported pseudoequilibrium of [123I]ADAM binding at 240-360 min after injection 
(217), and thus affect the reported finding. Better agreement was reached using the 
Logan model and acquisition time 0-120 min (223). Nevertheless, some uncertainty 
remains on the validity of the ratio method in quantification of SERT binding in studies 
using [123I]ADAM.   
 
For [123I]nor-β-CIT, initially the simple ratio method was used for SERT binding 
estimation (215). This has later been replaced by calculation of DVRs, using graphical 
reference tissue method without arterial sampling (112,328,329). No studies comparing 
these non-invasive methods with full kinetic modelling with arterial sampling have 
been published; some uncertainty thus remains on their agreement with full kinetic 
modelling when using [123I]nor-β-CIT.  
 
6.1.3. Relationship between 5-HT levels and SERT binding  
Despite the fact that numerous studies have been published on imaging of the brain 
SERTs, there is no firm consensus on the relationship between SERT binding and the 
synaptic 5-HT levels. The earliest SPET studies on SERT binding using [123I]β-CIT as 
a ligand found reduced SERT binding in conditions with presumed hyposerotonergic 
state and responsive to SSRI medication, e.g., MDD (339), seasonal affective disorder 
(340), alcoholism (116), and  BN (181). Our initial hypotheses were also based on this 
assumption. However, even though some later studies using the same ligand and more 
SERT-selective ligands have had similar results (115,335,341,342), others have found 
no differences between respective study populations (117,169,343,344) or have had 
opposite results (345,346).  
 
Theoretically, several different relationships are possible between extracellular 5-
HT levels and the SERT levels. For example, reduced 5-HT levels could be associated 
with either reduced or elevated binding of the radioligand to the transporter by the 
following mechanisms. Binding could be reduced: 
1. If reduction of extracellular 5-HT is caused by loss of serotonergic nerve 
terminals, leading to reduction in both SERT density and 5-HT (as in case of 
DAT binding in Parkinson’s disease in which loss of presynaptic dopaminergic 
neurons causes reduced DAT binding (347).  
2. If reduced 5-HT leads to reduction in SERT expression or increased 
internalization of the SERTs from the plasma membrane. Acute reductions in 5-
HT have been associated with reduced 5-HTT mRNA in animal studies 
(348,349), and this might reduce SERT expression and binding. Furthermore, in 
vitro studies have shown that SERT occupancy by 5-HT prevents the 
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internalization of SERTs from the plasma membrane (89), in which case 
reduced extracellular 5-HT could lead to internalization of SERTs into the 
cytosol and possibly to reduction in SERT binding. 
 
Alternatively, SERT binding might be increased: 
1. If increase in SERT density is the factor causative to or adding to the reduction 
of extracellular 5-HT. This view is supported by studies with SERT knockout 
mice, in which mice lacking SERTs show increased extracellular 5-HT (36). 
2. If reduced 5-HT increases SERT’s affinity for its ligands. 
3. If there is reduced endogenous competition by 5-HT for the binding sites. Such 
competition has been found to exist for [123I]-β-CIT (350), whereas results 
regarding selective SERT-ligand, [11C]DASB, are inconsistent (351-355). SERT 
ligands may differ from one another in this respect, making conclusions 
regarding the relationship even more difficult. To date, no studies have been 
published on endogenous competition by 5-HT with [123I]nor-β-CIT or 
[123I]ADAM. 
 
 
Further complexity to this picture may come from the lipophilicity of the SERT 
ligands. Lipophilicity is a necessary quality for a radioligand targeted to the brain, as it 
needs to cross the blood-brain barrier. However, due to lipophilicity, the radioligands 
used in brain imaging might also permeate the plasma membrane and enter the cell, and 
it has been suggested that radioligand binding techniques cannot discriminate cytosolic 
from surface transporter pools (356). This may be of importance in clinical studies, as 
the trafficking of SERTs between the plasma membrane and cytosol is one of the main 
events in the short term regulation of SERTs (34) and thus disease specific alterations 
particularly affecting this SERT distribution are possible. It is possible that radioligand 
studies are insensitive for this kind of alterations in the SERT densities, and differences 
may exist again between different SERT ligands.  
 
The complexity of relationship between 5-HT levels and SERT binding highlights 
the necessity for more studies addressing this relationship. Furthermore, this should be 
done for each radioligand separately, a fact which has been much neglected until 
recently.  
 
6.1.4. Other methodological considerations 
Most studies investigating the brain SERT binding have used cerebellum as the 
reference region. Based on earlier post mortem study results, cerebellum is nearly 
devoid of SERTs, showing considerably lower [3H]Paroxetine binding than other brain 
regions (326). It has therefore been considered as suitable reference region for 
estimating SERT binding in SPET and PET studies. However, displaceable SERT 
binding in the cerebellum has been shown for some SERT ligands, such as [11C]DASB 
and [11C]McN5652 (334), both in rat and monkey cerebellum. For [11C]DASB, also a 
human post mortem study reported displaceable SERT binding in the cerebellum, 
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showing highest specific SERT binding in the cerebellar vermis, followed by cerebellar 
grey matter and cerebellar white matter (357). It is presently thought that cerebellar 
vermis should not be included in the reference region, at least when using [11C]DASB. 
In our studies, cerebellar vermis was included in the reference region. In rat cerebellum, 
displaceable [123I]ADAM binding was detected, while no displaceable [123I]ADAM 
binding was evident in the monkey cerebellum (334). However, a recent study reported 
no displacement of SERT binding of [123I]ADAM from the cerebellum following 
infusion of citalopram, indicating that cerebellar binding of [123I]ADAM represents 
non-specific binding and supporting its use as a reference region (223). For [123I]nor-β-
CIT, pre-treatment with citalopram did not displace the radioligand from the 
cerebellum in monkeys (214); in humans, displacement data has been published only 
for regions with specific binding, the midbrain and striatum (215). For some reason, 
even selective SERT ligands seem to differ from one another in their binding to 
cerebellum (334). One suggested explanation is that different SERT ligands bind to 
different classes of SERTs, differing either in their affinity states or in their subcellular 
organization (e.g., plasma membrane vs. cytosol) (334). 
 
In all our studies comparing SERT binding between groups (studies II-IV), sample 
sizes were relatively small, but similar to sample sizes in many other SPET and PET 
studies. In reality, sample sizes are limited by the costs of an investigation as well as 
difficulties in finding study subjects that fit the inclusion and exclusion criteria. In 
studies II-IV, the sample sizes were smaller than we initially aimed for. In study II, 
three (out of 15) subjects dropped out, two of them because of technical problems in the 
SPET acquisitions. In study III, the number of BN cases was limited by the exclusion 
criteria (e.g., medications, tattoos (the subjects also went through MRIs), and by BN 
symptoms that in structured psychiatric interviews did not fulfil the diagnostic criteria. 
Also the number of unaffected co-twins was smaller than expected; the number of twin 
pairs concordant for BN was a surprise, and exclusion of male co-twins decreased the 
sample size of this group further. In study IV, only a small number of weight-
discordant twins were found despite screening thousands of twins. Therefore, these 
studies have the possibility of type II error due to small sample sizes. However, in study 
II we don’t consider this very likely, as there was not even a trend towards of 
difference in SERT binding between summer and winter scans. In study III, limited 
study power may have contributed to our inability to detect differences between BN 
women and the healthy women, and in study IV, to our inability to detect correlation 
between BMI and SERT binding in the individual data.  
 
We could not time all the SPET scans of the women to a particular phase of their 
menstrual cycle, as is often done in PET and SPET studies investigating the 
serotonergic system. Animal studies suggest that ovarian hormones may affect the 5-
HT system cyclically (145). In our studies timing the SPET scans to a particular phase 
of menstrual cycle was not possible, as the women in these studies were twins and the 
initial study designs were set to investigate twin-co-twin differences. We therefore 
prioritized scanning both twins at the same day instead of investigating them at a 
particular phase of their menstrual cycles. In study II, in which five unrelated women 
were studied twice, our aim was to time the second scan to the same phase of the 
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menstrual cycle as the first one, but for logistic reasons, this was possible only for three 
women. Therefore, although one SPET study found no differences in SERT binding in 
women scanned in their luteal phases as compared to the same women scanned at 
follicular phases (152), we cannot exclude the influence of the phase of menstrual cycle 
on the SERT binding estimates in women.   
 
6.2. Seasonal variation in the brain SERT binding  
 
In study II, we did not detect significant systematic variation between summer and 
winter data in SERT binding of healthy subjects in the SERT rich regions midbrain and 
thalamus. Our study was the first study to investigate within-subject seasonal variation 
in the brain SERTs. Some studies investigating platelet SERT (158-160) or 5-HT2A 
(158,161,162) binding have investigated seasonal within-subject variation, but their 
results have been inconsistent. Furthermore, two studies investigating the relationship 
between platelet SERT binding and the brain SERT binding found no obvious 
correlation between the central and peripheral measures (339,358), indicating that 
peripheral measures cannot be directly interpreted to represent respective central 
measures.  
 
Our results differ from the only previous study investigating the brain SERT 
binding (164), which reported lower SERT binding in the thalamus/hypothalamus in 
winter as compared to summer. However, the studies differ in the following aspects:  
1. We used a SERT-selective ligand, whereas the other study applied [123I]β-CIT. 
Even though [123I]β-CIT’s binding in the SERT rich regions thalamus, 
hypothalamus and midbrain has been considered as specific for SERTs 
(208,210), it nevertheless possesses affinities for DATs, and to some extent also 
to NETs (206-209). Our results thus reflect more reliably binding to SERTs, 
while theirs may have been affected by binding to other monoamine 
transporters. 
2. We investigated both sexes, and the other study investigated only women. 
However, this is unlikely to explain the discrepancy between the study results, 
as our study outcome was similar for both sexes.  
3. We investigated within-subject variation, and the other study investigated 
different subjects at different time points. Therefore, our study has less 
confounding variables.   
 
Small sample size was a weakness for both of these studies; in their case five 
women were investigated in summer and six women in winter, while in our case five 
women and seven men were investigated in both seasons. Even if our sample size is 
bigger, it may not be big enough considering the reported test-retest variability of 
[123I]ADAM (13% ± 11% in the midbrain and 16% ± 13% in thalamus (217) ). Similar 
consideration for [123I]β-CIT is prevented by the fact that no test-retest data for its 
SERT binding has been published. However, we do not believe limited study power 
explains our lack of significant seasonal variation, as we did not detect even any trend 
suggesting systematic seasonal variation. 
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 Although we did not find systematic within-subject differences in SERT binding 
between summer and winter, the results of the two scans showed considerable 
variability for some of the participants. This may be explained by the test-retest 
variability of [123I]ADAM, or by some other intra-subject changes in some 
unknown/unmeasured variables affecting SERTs. The subjects’ BMIs or ages did not 
explain this variability.  
 
Our study had some limitations that may have caused the fact that no seasonal 
variation was detected. Most importantly, there was no uniform and repeated 
psychiatric screening for the study subjects. Structured psychiatric interviews were 
performed only for women, who were interviewed by a psychiatrist before the winter 
scan but not before the summer scan; therefore, we cannot exclude some changes in 
their psychiatric status having taken place between the scans. For males, no structured 
psychiatric interviews were performed. Their classification as mentally healthy was 
based by their self-report and an interview by an MD, and some mild psychiatric 
problems may thus have not been detected. Therefore, mild psychiatric problems may 
have existed in some of the men in either or both scans, and in the women in the 
summer scans. Nevertheless, the within-subject study design reduces the likelihood of 
many other confounding variables. Secondly, four of our 12 study subjects smoked 
cigarettes. One study has reported an influence of smoking on SERT binding (136); 
however, to our knowledge, no studies using selective SERT ligands have attempted to 
replicate this finding. Again, the fact that within-subject changes were investigated is 
likely to reduce the influence of this possible confound. Thirdly, we cannot exclude 
with certainty the use of drugs affecting the 5-HT system in our study subjects, as we 
did not do blood screening to exclude their use, but instead trusted the subjects’ self-
report of non-use.  Fourthly, we could not time the scans of the two female subjects to 
the same phase of their menstrual cycle in both study occasions. We thus cannot 
exclude changes in their SERT binding caused by alteration of the levels of the ovarian 
hormones, even though this is unlikely based on the results of an earlier study 
investigating the variation in SERT binding between follicular and luteal phases (152).  
 
6.3. SERT BINDING IN SUBJECTS AFFECTED BY OR 
GENETICALLY PREDISPOSED TO BULIMIA NERVOSA 
 
Our a priori hypothesis of clearly reduced SERT binding in the women with BN as 
compared to their unaffected co-twins or unrelated healthy women was not borne out. 
There are several possible explanations for this result:  
 
1. SERTs are not affected in BN, but disturbances exist in other parts of the 
serotonergic system. The evidence favouring involvement of the serotonergic system in 
BN includes blunted neuroendocrine responses to drugs with 5-HT activity (265), 
worsening of symptoms after acute tryptophan depletion (269), the beneficial effect of 
fluoxetine in BN (16), and differences found in the brain PET- and SPET-studies in 
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SERTs (181) and 5-HT1A-receptors (270). The evidence favouring particularly the 
involvement of SERTs is scant; the beneficial effect of fluoxetine (16); alterations in 
the SERT binding of platelets in BN (359); and a SPET study reporting reduced SERT 
binding in the hypothalamus/thalamus in BN women (181). However, even though the 
SSRI medications are effective in BN and many other psychiatric diseases, their effect 
is not believed to be a direct effect on SERTs; one suggested mechanism is 
desensitization of somatodendritic 5-HT1A autoreceptors in the midbrain raphe nucleus, 
increasing 5-HT in critical brain regions (360), and other mechanisms are possible, too 
(see below).  Also, the results obtained from the previous SPET study may have been 
affected by the ligand’s ([123I]β-CIT) binding to DATs and NETs (213). The platelet 
SERT binding results do not necessarily correlate with SERT binding in the brain 
(358). Of the genetic association studies involving SERTs, one study has found an 
association between 5-HTTLPR genotype and BN (252), but other studies have not 
replicated the finding (253,254).  
 
2. SERTs are affected in BN, but in other regions than were investigated in our 
study. The ligand used in our study, [123I]ADAM, has acceptable test-retest 
repeatability in the midbrain and thalamus, whereas in other regions its binding is more 
variable (217). We thus investigated SERT binding in these two regions only. The 
midbrain region containing the raphe nuclei has the highest SERT density (361) and 
[123I]ADAM binding (217), and is therefore of special interest. The 
hypothalamus/thalamus is the region with the second greatest [123I]ADAM binding 
(217) and is of interest also for its proximity to hypothalamus (these areas cannot be 
distinguished reliably by SPET), which is the brain area involved in the control of 
feeding behavior (362). Nevertheless, alterations in SERT density in BN are possible in 
other brain regions. 
 
3. Serotonergic system is not primarily affected, but the previously reported 
alterations are secondary to some other neurobiological alterations. So far, the 
investigations on the neurobiology of BN have mainly concentrated on the serotonergic 
system, but other neurotransmitters, neuropeptides, intracellular signalling cascades etc. 
may also be involved. Regarding the effect of fluoxetine (16), effects other than direct 
effects on the serotonergic system are possible. In addition to desensitization of 
somatodendritic 5-HT1A autoreceptors in the midbrain raphe nucleus (360), suggested 
mechanisms of action of the SSRI medications include modulation of the homeostasis 
between different neurotransmitters (363) and activation of the various intracellular 
signalling pathways and their downstream targets that promote expression of genes 
promoting neurogenesis (364).  
 
4. SERTs are affected in the investigated regions, but we failed to detect differences 
due to methodological reasons. Firstly, the considerable test-retest variability of 
[123I]ADAM binding (217) may necessitate bigger sample sizes than were investigated 
in our study. When BN probands were compared with all healthy subjects (including 
unaffected co-twins of the probands) there was a nonsignificant trend towards higher 
SERT binding in the midbrain (p=0.08). This difference might have been significant 
with a bigger sample. Secondly, a recent study questioned the validity of the simple 
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ratio method in the estimation of SERT binding in [123I]ADAM studies (223); it is thus 
possible that differences would have been evident had we used other quantification 
methods, e.g. the Logan reference tissue model (223). Thirdly, due to the nature of the 
sample (population-based rather than clinic-based), the BN probands in our study may 
have been affected by milder disease than in the previous SPET study (181), thus 
affecting the discrepancy between the results. Fourthly, the fact that we could not 
control for the phase of the menstrual cycle might have affected our study results, 
causing more variation in SERT binding.  
 
Even though our a priori hypothesis was not borne out, in post hoc analyses we 
found a significantly higher SERT binding in the midbrain region of the purging BN 
women (n=9) as compared to all healthy women (n=24). This suggests that purging and 
non-purging BN patients may differ neurobiologically, with respect to their SERT 
function or some other phenomenon reflecting to SERT binding. Purging bulimics have 
been found to differ from non-purging ones in certain personality variables (e.g. lower 
self-directedness, organization, personal standards, and higher novelty seeking) (365); 
neurobiological differences may thus be possible, too. It is also possible that 
serotonergic or SERT alterations are not specific for BN as such, but instead found in 
subjects with particular characteristics associated with BN. For example, some studies 
not finding an association between BN and 5-HTTLPR polymorphism have found an 
association between the 5-HTTLPR genotype and particular predisposing eating 
disorder-related behavioral and attitudinal traits (254-256). We did not investigate the 
association of SERT binding and particular personality characteristics. A further 
possibility is that increased SERT binding in the purging probands is secondary to 
purging bulimic behaviour, e.g., through alterations in nutritional status affecting 5-HT 
levels or SERT expression.  
 
Our a priori hypothesis was reduced SERT binding in BN. Instead, in the post hoc 
analyses we found higher SERT binding in the purging BN probands, a finding 
opposite to the initial hypothesis. The possible alternatives for the relationships 
between 5-HT and SERT levels are discussed in section 6.1.3. It is possible that this 
relationship is radioligand specific, perhaps affected by differences in endogenous 
competition by 5-HT, or by differences regarding SERT subclasses the ligand binds to 
(334). Radioligand specific differences might thus explain the opposite results of the 
present and the previous study (181). At the moment, the reasons behind our finding 
can only be speculated. Considering the prevailing theory of reduced 5-HT firing in 
BN, our finding might represent secondarily increased affinity of the SERTs or reduced 
competition for the binding sites. Alternatively, the purging BN women might have 
primarily increased SERT expression, causing reduced extra-cellular 5-HT levels, 
reduced serotonergic firing, and the symptoms associated with purging BN, or the 
increase in SERT expression might be secondary to purging bulimic behavior. 
 
We also hypothesized a BN associated trait in SERT binding. If such trait existed, 
the unaffected co-twins of BN probands would have had SBR values intermediate 
between the BN probands and unrelated controls, given that our sample included both 
MZ and DZ twin pairs. Against our initial hypothesis, the unaffected co-twins had 
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similar SERT binding as unrelated healthy controls. However, the small number of 
unaffected co-twins (made smaller by the unexpectedly many concordant pairs as well 
as by exclusion of male co-twins), reduces the reliability of this conclusion. The small 
number also prevented further subgroup analyses based on zygosity or the BN subtype. 
Therefore, we cannot suggest whether the increased SERT binding in purging BN is 
caused by genetic or environmental factors. The initial decision to include two currently 
asymptomatic women in the group of BN women was based on the assumption of a 
genetic trait. In post hoc analyses, removal of these two subjects did not affect our 
results. 
 
Our sample of BN women fits well to the prevailing view of BN subjects, with the 
onset of their symptoms (around 18 years of age) (14), with their past history of 
anorexic symptoms (five subjects) (233,236) and history of major depression (seven 
with past MDD and one with current MDD) (14,232). Histories of AN and MDD could 
be considered as confounds when studying SERT binding in BN. However, finding a 
big enough sample of subjects without past co-morbidities is extremely difficult. In a 
large population-based sample, 94.5% of subjects with lifetime BN met criteria for at 
least 1 of the core DSM-IV disorders, and 70.7 % for a mood disorder (including MDD, 
dysthymia and bipolar disorders (14). Our sample is thus well representative of BN 
patients. In statistical analyses of our data, past AN or MDD had no effect on our 
results. The ratio of purging vs. non-purging BN cases in our sample was 2.25:1; this 
ratio is bigger than in another population sample (reporting the ratio of life-time 
prevalence as 1:1) (233), but smaller than is reported in clinical sample (233).  
 
6.4. Association between SERT binding and BMI 
 
In study IV, we investigated the association between BMI and SERT binding in a 
sample of monozygotic twins, who were analyzed as individuals and as pairs. 
Individual data was used to study associations between variables caused by both 
genetic and non-genetic factors. Within-pair comparisons eliminated the effect of genes 
and shared environmental experiences on investigated relationships. 
 
Our main finding was that twins with higher BMI had higher SERT binding than 
their co-twins in the hypothalamus/thalamus. The fact that the association was evident 
in within-pair comparisons of genetically similar co-twins but not in individual data 
suggests that the association is not caused by genetic factors, but is a product of 
environmental influences.  
 
As discussed earlier in section 6.1.3., there is no clear consensus on the association 
of brain 5-HT levels and SERT binding in the brain imaging studies. The relationship 
may vary between different ligands, depending on whether the ligand competes with 
the endogenous substrate or not. Furthermore, even for one ligand the finding may 
represent different things in different settings. The measured SERT binding could 
theoretically be affected by: the actual number of 5-HT neurons; the number of SERTs 
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(affected e.g., by genetic polymorphism, epigenetic effects on SERT expression, and by 
various regulatory mechanisms acting in the short or long term); or by alterations in the 
5-HT levels, causing alteration in SERT binding as a result of feedback mechanisms, 
altered competition with the endogenous ligand, or altered affinities. Not enough is 
known about this relationship to allow a reliable interpretation of study results, and it 
should be emphasized that all efforts to do so remain speculative.  
 
Based on the existing data on the association of 5-HT with feeding behavior, 5-HT 
has long been considered as an anorexigenic signalling factor causing hypophagia and 
promoting the feeling of satiety (11). The precise mechanisms of its actions are still not 
fully understood but seem to involve multiple 5-HT receptors and downstream targets 
of other signalling systems involved in the regulation of feeding behavior (302,304). 
Several studies have also found differences relating to the 5-HT system between obese 
and lean animals and humans. Obese rats have lower brain 5-HT levels compared to 
lean rats (296). In humans, obese subjects have been found to have lower plasma levels 
of tryptophan than lean subjects (297,298), which is thought to lead to lower levels of 
brain 5-HT, which could lead to impaired satiety and enhanced feeding behavior. So 
differences may exist in the supply of 5-HT between the obese and lean subjects. 
Alternatively, alterations affecting primarily the brain are possible, e.g. alterations in 
different aspects of the 5-HT system, as has been suggested, e.g., by genetic association 
studies that have found associations between BMI and overweight with polymorphism 
of various genes affecting the 5-HT system (306-309,313,314).  
 
Against this background, two interpretations for the increased SERT binding in the 
subjects with higher BMI seem plausible: Increased SERT binding is secondary to 
reduced levels of brain 5-HT (secondary to reduced supply of tryptophan) causing 
increased affinity and/or reduced endogenous competition for SERT binding; this 
interpretation remains speculative as we did not measure plasma tryptophan levels.  
Alternatively, SERT densities could be increased and cause reduced synaptic 5-HT 
levels and neuronal firing, leading to impaired satiety and weight gain. This would be 
unlikely to represent direct genetic influences, as we found different SERT binding 
between members of genetically similar twins. At the moment, there is more evidence 
to favour the first interpretation than the second one (297,298).  
 
Recent studies have shed light on the reasons behind discordance of monozygotic 
twins. Despite being genetically identical, the twins may differ significantly in their 
phenotype. The twins may develop under influence of different environmental factors 
already during their fetal life, and later on the environmental effects add on. Epigenetic 
influences (affecting gene expression without affecting the DNA sequence) may be 
behind the discordance of MZ twins.  Epigenetic differences between MZ twins have 
been detected for example in histone acetylation and DNA methylation. These 
differences are significantly more common in older than younger twins, and in twins 
who have been exposed to more environmental differences (316). In our study, 
epigenetic differences might be behind differences in levels of tryptophan and/or 5-HT, 
or cause differences in SERT expression. However, it remains unknown, whether 
differences in adiposity and weight gain are the cause or consequence of different 
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SERT binding. Instead of reduced 5-HT levels causing impaired satiety and increased 
weight gain, differences in external factors such as diet might cause epigenetic 
differences (366) affecting the 5-HT system. Furthermore, differences in personality 
characteristics relating to 5-HT system and associating with weight gain are possible.  
 
When the within-pair data were analyzed separately for both sexes, the intra-pair 
difference in SERT binding in the hypothalamus/thalamus was significant only in 
women. Sexual dimorphism of the 5-HT system has been observed in several studies. 
In humans, the rate of the brain 5-HT synthesis is reported to be lower in women, and 
also the effects of tryptophan depletion on the rate of 5-HT synthesis (134), as well as 
its mood effects (135), are stronger in women than in men. Sex differences are also 
reported in the brain 5-HT1A (137,138) and SERT binding (136,137), and different 
SERT binding between men and women was seen in our data, too (higher SERT 
binding in men in the midbrain area). Sex-related differences also exist in the 
prevalence and presentation of MDD (119), in which disturbed 5-HT function is 
implicated (5), and a previous study reported sex-specific differences in SERT binding 
between depressed men and women (341). Our results suggest that the association of 
BMI and SERT binding is also different between men and women. One possible 
explanation could be that if women have a relatively lower 5-HT function (as suggested 
by e.g., lower rates of 5-HT synthesis (134) and greater vulnerability to effects of 
tryptophan depletion (135)), also the effects of lower levels of plasma tryptophan 
(297,298) are more pronounced and evident in SERT binding in women. Sexual 
dimorphism has also been found in appetite, women having a relatively stronger 
preference for carbohydrates over proteins and fats than men (367). This difference in 
appetite has been suggested to relate to 5-HT, which affects the intake of carbohydrates 
more than it affects the intake of proteins or fats (362).  
 
In individual data, no correlation between BMI and SERT binding was evident. This 
may be explained by the multitude of factors (genetic and environmental) that may 
cause differences in SERT binding between individuals. In MZ pairs, confounding due 
to genetic effects is eliminated in twin–co-twin comparisons and also many 
environmental factors are similar for monozygotic twins reared together.  
 
Despite of being a result post hoc analysis, it is of interest that women using oral 
contraceptives had significantly reduced SERT binding in the hypothalamus/thalamus 
as compared to women without oral contraceptives. Exclusion of women with oral 
contraceptives did not affect our study results. To our knowledge, no previous PET or 
SPET studies on SERTs have addressed the effect of oral contraceptives or other 
exogenous synthetic estrogens. Considering how common these medications are, their 
influence may be a potential confound in studies of the brain 5-HT system and should 
therefore be addressed in future studies.  
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7. SUMMARY AND CONCLUSIONS 
 
The main conclusions of the work presented in this thesis can be summarized as 
follows: 
 
1. Definition of volumes of interest (VOIs) for purposes SERT binding 
quantification of [123I]ADAM images is more reproducible using automated 
placement of predefined VOIs on stereotactic images than using manual VOI-
drawing on non-stereotactic images (I). 
2. SERT binding in the midbrain and thalamus regions is similar in summer and 
winter, suggesting that seasonal variation is not a significant confound in SERT 
imaging studies of these regions (II). 
3. In a population-based sample, SERT binding in the midbrain and thalamus of 
women affected by Bulimia Nervosa is not different from their healthy twin 
sisters or other healthy women. In purging BN women SERT binding in the 
midbrain region may be increased as compared to healthy women (III). 
4. SERT binding in hypothalamus/thalamus is increased in acquired obesity in 
women. This association is not genetic but a consequence of environmental 
influences (IV). 
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